Amedeo Smart

Free Medical Literature Service

 

Amedeo

HIV Infection
  Free Subscription

Articles published in
J Acquir Immune Defic Syndr
    December 2025
  1. TIEN D, Chandiwana N, Shazi G, Chen G, et al
    Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.
    J Acquir Immune Defic Syndr. 2025 Dec 2. doi: 10.1097/QAI.0000000000003812.
    >> Share

  2. D'ANGELO AB, Patel VV, Carrico AW, Grov C, et al
    To err is human, to persist is diabolical: Are we repeating the same cost and insurance coverage mistakes again with injectable PrEP?
    J Acquir Immune Defic Syndr. 2025 Dec 2. doi: 10.1097/QAI.0000000000003817.
    >> Share

  3. RASKOPF W, Mbewe E, Adams H, Buda A, et al
    a. Nutritional Status and Cognitive Function in Children with or exposed to HIV: Evidence from the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study.
    J Acquir Immune Defic Syndr. 2025 Dec 2. doi: 10.1097/QAI.0000000000003811.
    >> Share

  4. MPOFU R, Chandiwana N, Sokhela S, Moorhouse M, et al
    The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis.
    J Acquir Immune Defic Syndr. 2025 Dec 2. doi: 10.1097/QAI.0000000000003810.
    >> Share

    November 2025
  5. SERGHIDES L, Lee J, Jacobson DL, Geffner ME, et al
    Is gestational exposure to HIV and protease inhibitors associated with timing of pubertal onset?
    J Acquir Immune Defic Syndr. 2025 Nov 19. doi: 10.1097/QAI.0000000000003801.
    >> Share

  6. NALUGGA EA, Musaazi J, Manabe YC, Kalema N, et al
    Adverse drug reactions related to isoniazid preventive therapy among persons living with HIV on dolutegravir-based regimens in Uganda between July 2019 and March 2020.
    J Acquir Immune Defic Syndr. 2025 Nov 19. doi: 10.1097/QAI.0000000000003802.
    >> Share

  7. ONOYA D, Shumba K, Mudara C, Nattey C, et al
    Timing of ART initiation with treatment policy changes in South Africa: a cohort study.
    J Acquir Immune Defic Syndr. 2025 Nov 18. doi: 10.1097/QAI.0000000000003797.
    >> Share

  8. BASSETT IV, Yan J, Govere S, Johnson LS, et al
    PrEP and contraceptive persistence among young women receiving sexual and reproductive health services through hair salons in South Africa.
    J Acquir Immune Defic Syndr. 2025 Nov 18. doi: 10.1097/QAI.0000000000003800.
    >> Share

  9. ALVAREZ JA, Teeny S, Yang CA, Mehta CC, et al
    Altered lipid and neurotransmitter metabolism as potential mechanisms of weight gain in women with HIV initiating INSTIs in a pilot study.
    J Acquir Immune Defic Syndr. 2025 Nov 18. doi: 10.1097/QAI.0000000000003799.
    >> Share

  10. GRAYBILL LA, Huffstetler HE, Mtande TK, Krysiak R, et al
    Identifying pregnant women at high risk of HIV acquisition: An external validation assessment of an HIV risk assessment tool for pregnant women.
    J Acquir Immune Defic Syndr. 2025 Nov 17. doi: 10.1097/QAI.0000000000003798.
    >> Share

  11. HALLMARK CJ, France AM, Linley L, Lyss SB, et al
    Characteristics of HIV Time-Space Alerts in the United States, 2018-2021.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003795.
    >> Share

  12. DRUMRIGHT LN, Delaney JA, Crawford T, Whitney BM, et al
    Longitudinal associations between internalized HIV stigma and lower HIV antiretroviral therapy adherence among people with HIV.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003793.
    >> Share

  13. LAXMESHWAR C, Hegde A, Dange A, Mariyappan K, et al
    Virtual model for HIV self-testing demand generation and kit distribution: Results from the STAR III study in India.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003792.
    >> Share

  14. NGUYEN T, Chae JW, Ziemba L, Coletti A, et al
    Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003796.
    >> Share

  15. WAMAKIMA B, Diouf K, Modest A, Macharia A, et al
    Pre-eclampsia Rates in Women with and without HIV in Modern ART Era in Botswana.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003791.
    >> Share

  16. UMUTONI V, Eavou R, Almirol E, Neumann MS, et al
    A Community Located Insurance Navigation Intervention to link Sexual and Gender Minorities in Status Neutral Care: Results from the NICE Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 Nov 3. doi: 10.1097/QAI.0000000000003788.
    >> Share

    October 2025
  17. KHANNA A, Lee F, Schrode K, Sheeler D, et al
    Long-acting injectable PrEP can substantially reduce HIV incidence in Los Angeles County: A simulation study.
    J Acquir Immune Defic Syndr. 2025 Oct 30. doi: 10.1097/QAI.0000000000003790.
    >> Share

  18. IQBAL K, Crim SM, Tie Y, Cholli P, et al
    Availability of substance use services at U.S. HIV care facilities by urbanicity.
    J Acquir Immune Defic Syndr. 2025 Oct 28. doi: 10.1097/QAI.0000000000003789.
    >> Share

  19. KEDDEM S, Sorrentino A, Agha AZ, Colt SF, et al
    Exploring PrEP Uptake in Young Women Veterans: Insights from a Detailed Chart Review within the Veterans Health Administration.
    J Acquir Immune Defic Syndr. 2025 Oct 24. doi: 10.1097/QAI.0000000000003782.
    >> Share

  20. MAGONGO EN, Hast M, Nabitaka V, Nakanwagi M, et al
    Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir amongst Children Living with HIV Failing on First-line Antiretroviral Therapy in Uganda.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003784.
    >> Share

  21. ADESSE D, Torices S, Alcaide ML, Beurel E, et al
    Plasma biomarkers of neurogenesis are increased among people with HIV after COVID.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003785.
    >> Share

  22. LARSON ME, Pan Y, Lakhani F, Chavez J, et al
    The association between cannabis use and electrocardiographic abnormalities in people living with HIV.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003786.
    >> Share

  23. ORKIN C, Kuritzkes DR, Katlama C, Su FH, et al
    Doravirine Resistance Patterns Identified through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003787.
    >> Share

  24. D K, C R, B C, H RG, et al
    Factors Associated with Preference for Long-Acting Injectable versus Daily Oral Antiretroviral Therapy among People with HIV: Findings from the SELIGO Study.
    J Acquir Immune Defic Syndr. 2025 Oct 22. doi: 10.1097/QAI.0000000000003781.
    >> Share

  25. ISLEK D, Sanchez T, Baral S, Caldwell JA, et al
    Characteristics associated with the HIV Pre-exposure prophylaxis care continuum among transfeminine persons in the United States.
    J Acquir Immune Defic Syndr. 2025 Oct 22. doi: 10.1097/QAI.0000000000003783.
    >> Share

  26. MCHENRY MS, Huo Y, Williams PL, Patel K, et al
    Plasma inflammatory biomarkers lack strong association with cognitive outcomes among young adults with perinatal HIV exposure and/or acquisition.
    J Acquir Immune Defic Syndr. 2025 Oct 14. doi: 10.1097/QAI.0000000000003771.
    >> Share

  27. HSUE PY, Behrens GMN, Xu ZJ, Zhao Y, et al
    Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
    J Acquir Immune Defic Syndr. 2025 Oct 13. doi: 10.1097/QAI.0000000000003778.
    >> Share

  28. ROSENBERG NE, Young AM, Zou Y, Justman J, et al
    An HIV-1 risk assessment tool for men aged 15-59 years in 13 African countries: A pooled analysis of nationally representative surveys.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003773.
    >> Share

  29. DAHAL S, Logan J, Kanagasabai U, Annor F, et al
    Differential associations of violence and mental health outcomes by HIV status among adolescent girls and young women aged 15-24 years in 5 countries in Sub-Saharan Africa, 2018/2019.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003769.
    >> Share

  30. CEBULA BR, Frndak S, Hamby T, Esber A, et al
    COVID-19 Knowledge, Attitudes, and Practices among People with and Without HIV in Four Countries in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003770.
    >> Share

  31. CHANDRAN A, Olson S, Edmonds A, Moran CA, et al
    Trajectories of BMI Before, During and Following the COVID-19 Pandemic among Participants in the MACS/WIHS Combined Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003779.
    >> Share

  32. WEINSTEIN ER, Kirakosian N, Chen YO, Bharat B, et al
    Life Instability and its Effects on Psychosocial Syndemic Problems and HIV-Care Outcomes in People Living with HIV in Care in South Florida.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003777.
    >> Share

  33. ALFORD K, Fitzpatrick C, Rhodes S, O'Brien C, et al
    Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway.
    J Acquir Immune Defic Syndr. 2025 Oct 8. doi: 10.1097/QAI.0000000000003775.
    >> Share

  34. FIEGGEN J, Meintjes G, Boulle A, Euvrard J, et al
    Characteristics of Individuals with Advanced HIV Disease and Risk Factors for Mortality in a Contemporary Cohort in South Africa.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003767.
    >> Share

  35. BHUSHAN NL, Boudewyns V, Getachew-Smith H, Stryker JE, et al
    Pre-Exposure Prophylaxis (PrEP) Guideline Awareness and Prescribing Behaviors Among Healthcare Providers in the United States: DocStyles Survey, 2022-2024.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003774.
    >> Share

  36. STEVENSON M, Cooney E, Borquez A, Radix AE, et al
    Undiagnosed HIV among transgender women in the United States: Implications for testing programs.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003776.
    >> Share

    September 2025
  37. VYAS KJ, Moreland S, Esser S, Jessen H, et al
    Trends in Online and In-Person Sex-Seeking Venues among Men who have Sex with Men in Berlin, Germany.
    J Acquir Immune Defic Syndr. 2025 Sep 25. doi: 10.1097/QAI.0000000000003766.
    >> Share

  38. HENRY RT, Khol V, Duy CD, Marbaniang I, et al
    Low Cholesterol associated with TB in people living with HIV in an Asia-Pacific cohort.
    J Acquir Immune Defic Syndr. 2025 Sep 18. doi: 10.1097/QAI.0000000000003761.
    >> Share

  39. MELNYCHUK S, Green K, Ejeckam C, Adesina A, et al
    HIV drug resistance among key populations in Nigeria: Insights from the 2020 integrated biological and behavioural surveillance survey.
    J Acquir Immune Defic Syndr. 2025 Sep 11. doi: 10.1097/QAI.0000000000003763.
    >> Share

  40. STRACKER N, Rives S, Schumacher CM, Hamill MM, et al
    Addressing Health Disparities Associated with the HIV PrEP Initiation Cascade, Baltimore City Health Department Sexual Health Clinics, 2016-2023.
    J Acquir Immune Defic Syndr. 2025 Sep 11. doi: 10.1097/QAI.0000000000003764.
    >> Share

  41. CARROZZO G, Pozza G, Poloni A, Caronni S, et al
    Evolution of causes of death in People with HIV between 2000 and 2023: a single center retrospective Study.
    J Acquir Immune Defic Syndr. 2025 Sep 10. doi: 10.1097/QAI.0000000000003762.
    >> Share

  42. KELLY NK, Ranapurwala SI, Pence BW, Hightow-Weidman LB, et al
    The effect of state-level policy climate on HIV pre-exposure prophylaxis use and the role of internalized stigma.
    J Acquir Immune Defic Syndr. 2025 Sep 4. doi: 10.1097/QAI.0000000000003760.
    >> Share

  43. MORGAN E, McDade TW, Manning W, Kamp Dush CM, et al
    Assessing Inflammatory Biomarkers at the Intersection of Marijuana and PrEP Use: Preliminary findings from the NCHAT-BIO study.
    J Acquir Immune Defic Syndr. 2025 Sep 4. doi: 10.1097/QAI.0000000000003759.
    >> Share

  44. KNETTEL BA, Madundo K, Amiri I, Msoka EF, et al
    Results of a Pilot Randomized Controlled Trial of IDEAS for Hope, a Brief Telehealth Intervention for Suicide Prevention and HIV Care Engagement in Tanzania.
    J Acquir Immune Defic Syndr. 2025 Sep 4. doi: 10.1097/QAI.0000000000003758.
    >> Share

  45. SPENCE AB, Visconti A, Goparaju L, Wingood G, et al
    Anticipated protection overcomes vaccine hesitancy and mistrust among women enrolled in the DC MACS/WIHS Combined Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Sep 3. doi: 10.1097/QAI.0000000000003757.
    >> Share

    August 2025
  46. FRIEDLAND BA, Browne EN, Roberts ST, Ngure K, et al
    Higher acceptability of the monthly dapivirine ring versus daily oral pre-exposure prophylaxis among adolescent girls and young women in sub-Saharan Africa in the REACH trial.
    J Acquir Immune Defic Syndr. 2025 Aug 28. doi: 10.1097/QAI.0000000000003756.
    >> Share

  47. WANG H, Kolstee J, Gaetani M, Aphami L, et al
    Interest in and preference for long-acting injectable PrEP among men who have sex with men, trans* individuals, and cis-gender heterosexual women: a global systematic review and meta-analysis.
    J Acquir Immune Defic Syndr. 2025 Aug 27. doi: 10.1097/QAI.0000000000003754.
    >> Share

  48. D'ANTONI ML, Boopathy AV, Andreatta K, Chang S, et al
    HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003749.
    >> Share

  49. QIAN Y, Comulada WS, Hidalgo MA, Lee SJ, et al
    Depression improves the predictive accuracy of the VACS Index 2.0 for all-cause mortality among sexual minority men living with HIV in the Multicenter AIDS Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003752.
    >> Share

  50. MADLALA HP, Jao J, Roussos G, Mendham AE, et al
    Gluteal adipose tissue mitochondrial respiration and insulin sensitivity in pregnant South African women living with HIV on Tenofovir-Lamivudine-Dolutegravir.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003755.
    >> Share

  51. BERRY DL, Orr JE, Schmickl CN, DeYoung Rpsgt P, et al
    Effects of Treating Obstructive Sleep Apnea on Common Symptoms of HIV.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003753.
    >> Share

  52. CHIROMBO J, Lora WS, Sakala D, Shahmanesh M, et al
    An exploratory study using respondent-driven sampling to map HIV risk across sex work locations in Blantyre, Malawi.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003746.
    >> Share

  53. MOYO S, Yankinda EK, Hurwitz KE, Bennett K, et al
    Predictors of Concurrent Sexual Partnerships and Association with Recent HIV Infection in a Large Population-Based Survey in Botswana.
    J Acquir Immune Defic Syndr. 2025 Aug 22. doi: 10.1097/QAI.0000000000003751.
    >> Share

  54. KALATA NL, Bello G, Pals S, Kabaghe AN, et al
    HIV Drug Resistance to Dolutegravir Among Adults Investigated for Anti-retroviral Treatment Failure in Malawi: A 2023 National Cross-sectional Survey.
    J Acquir Immune Defic Syndr. 2025 Aug 21. doi: 10.1097/QAI.0000000000003744.
    >> Share

  55. JONES J, Schneider I, Valencia R, Jenness SM, et al
    Randomized controlled trial of a HIV prevention app to increase pre-exposure prophylaxis uptake among gay and bisexual men who have sex with men in the United States: The HealthMindr PrEP study.
    J Acquir Immune Defic Syndr. 2025 Aug 19. doi: 10.1097/QAI.0000000000003747.
    >> Share

  56. YANG G, Dale I, Zarwell M, Elkins JS, et al
    Harnessing Egocentric Networks to Inform an Enhanced Social Network Strategy in a Southern US "Ending the HIV Epidemic" Region.
    J Acquir Immune Defic Syndr. 2025 Aug 19. doi: 10.1097/QAI.0000000000003750.
    >> Share

  57. CHANG GC, Bingham T, Patel HK, Mungai E, et al
    Undetectable HIV-1 viral load among virally suppressed people living with HIV: implications for Undetectable equals Untransmittable (U=U) in resource-limited settings using dried spot testing.
    J Acquir Immune Defic Syndr. 2025 Aug 15. doi: 10.1097/QAI.0000000000003745.
    >> Share

  58. HAY WONG JM, Balleny R, Lee T, Bitnun A, et al
    Perinatal and early infant outcomes after bictegravir exposure in pregnancy: a Canadian surveillance study.
    J Acquir Immune Defic Syndr. 2025 Aug 14. doi: 10.1097/QAI.0000000000003708.
    >> Share

  59. COMINS CA, Genberg B, Mcingana M, Bandeen-Roche K, et al
    Longitudinal trajectories of engagement with HIV treatment support strategies among female sex workers living with HIV in South Africa.
    J Acquir Immune Defic Syndr. 2025 Aug 14. doi: 10.1097/QAI.0000000000003738.
    >> Share

  60. BOOPATHY AV, D'Antoni ML, Andreatta K, Chang S, et al
    Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Participants with Preexisting K65R/N in HIV-1 in Phase 2/3/3b Clinical Trials.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003742.
    >> Share

  61. DZOMBA A, Shumba K, Nattey C, Lauren E, et al
    HIV patient treatment adherence trajectories in first 24-months post-ART initiation among adults: an electronic health records cohort from South Africa.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003736.
    >> Share

  62. PALOMARES M, Shade SB, Pollack L, Zand P, et al
    Enthusiasm for Participation in a Novel, At-Home Delivery Model for Injectable HIV Treatment among People with HIV.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003743.
    >> Share

  63. NJUGUNA I, Maleche-Obimbo E, Mugo C, Begnel ER, et al
    Herpesvirus viremia, ART response, and growth recovery in Kenyan children starting antiretroviral therapy in hospital.
    J Acquir Immune Defic Syndr. 2025 Aug 7. doi: 10.1097/QAI.0000000000003741.
    >> Share

  64. HIGGINS N, Patel N, Solso S, Dullano C, et al
    Relationship between Opioid Use, Depression and Quality of Life among Persons with HIV at End of Life.
    J Acquir Immune Defic Syndr. 2025 Aug 4. doi: 10.1097/QAI.0000000000003737.
    >> Share

  65. NUTT CT, Muyindike WR, Nanfuka V, Komukama N, et al
    Factors Associated with Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda.
    J Acquir Immune Defic Syndr. 2025 Aug 4. doi: 10.1097/QAI.0000000000003735.
    >> Share

  66. ROSEN JG, Esso Y, Keugoung B, Lwamba C, et al
    Sexual partnership heterogeneity and HIV seropositivity among adolescent girls and young women in Cameroon and Cote d'Ivoire: a partner-level latent class analysis.
    J Acquir Immune Defic Syndr. 2025 Aug 1. doi: 10.1097/QAI.0000000000003740.
    >> Share

  67. MCGILL LS, Clay OJ, Edwards KA, Jones KF, et al
    Trajectories of Pain Impact and Pain Self-Efficacy in People with HIV and Chronic Pain: Extending Findings from the Skills TO Manage Pain (STOMP) Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2025 Aug 1. doi: 10.1097/QAI.0000000000003739.
    >> Share

    July 2025
  68. MOODY K, Verburgh ML, Stutterheim SE, F Schim Van Der Loeff M, et al
    Stigma-related disclosure concerns and negative self-image have not improved over a decade in older people with HIV.
    J Acquir Immune Defic Syndr. 2025 Jul 28. doi: 10.1097/QAI.0000000000003732.
    >> Share

  69. WONG IKJ, Dyer CEF, Grulich AE, Jin F, et al
    Anal Cancer Screening in People Living with HIV: A Pilot Study of Primary HPV Screening with Triage Use of p16/Ki67 Dual Stain.
    J Acquir Immune Defic Syndr. 2025 Jul 28. doi: 10.1097/QAI.0000000000003731.
    >> Share

  70. BYAKWAGA H, Semeere A, Laker-Oketta M, Busakhala N, et al
    Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the "Treat-All" Era.
    J Acquir Immune Defic Syndr. 2025 Jul 28. doi: 10.1097/QAI.0000000000003733.
    >> Share

  71. MOTLHAOLENG K, Vilakazi-Nhlapo K, Shearer K, Golub JE, et al
    Characterization of the targeted universal tuberculosis testing care cascade among people with HIV in PEPFAR-supported districts in South Africa.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003729.
    >> Share

  72. SALAZAR J, Coffey S, Bloome J, Hickey MD, et al
    Outcomes of Rapid Restart among People with Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003727.
    >> Share

  73. CONLEY H, Oh SY, Garrett N, Kublin J, et al
    IgG and Fc receptor genetic variation associates with functional antibody responses in a DNA and protein candidate HIV vaccine trial.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003734.
    >> Share

  74. KUNKEL A, Alioum A, Lot F, Cazein F, et al
    HIV incidence, migration and diagnosis dynamics, France, 2012-2023: a surveillance and modeling data analysis.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003730.
    >> Share

  75. GANGULY S, Christman O, Yang Q, Mehta C, et al
    Influence of Housing Status on Health Outcomes for Reproductive-Age Women With and Without HIV in the Southern United States.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003722.
    >> Share

  76. CABELLO-UBEDA A, Lopez Bernardo de Quiros JC, Mena A, Torralba M, et al
    Dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naive adults with HIV with and without genotypic resistance testing results. 96-Week effectiveness and tolerability of REDOLA study.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003721.
    >> Share

  77. ANDERS J, Freeman A, Hou B, Sone P, et al
    HIV testing among transgender and other gender diverse persons in the United States: A scoping review.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003728.
    >> Share

  78. JADALLAH HG, O'Connor LF, Byrne M, Baskaran A, et al
    Understanding the Impact of Antiretroviral Therapy and Other Factors on HPV Clearance in Cisgender Women with HIV/HPV Co-infections in the DC Cohort.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003726.
    >> Share

  79. RODRIGUEZ AE, Botero V, Geffrard A, Saltzman RG, et al
    Entering HIV Medical Care with AIDS in the Era of Immediate Access to Antiretroviral Treatment.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003725.
    >> Share

  80. GOVENDER NP, Greene GS, Hullsiek KH, DeSanto D, et al
    Effectiveness of a national reflex laboratory cryptococcal antigen screening programme for people with advanced HIV disease in South Africa: a nationwide-sampled cohort study (CAST-NET).
    J Acquir Immune Defic Syndr. 2025 Jul 15. doi: 10.1097/QAI.0000000000003724.
    >> Share

  81. MARANO-LEE M, Williams W, Xu S, Uhl G, et al
    Adults Aged >/=50 Years Reached by the CDC's HIV Programs Including HIV Testing, PrEP Referrals, and Linkage to Care in the U.S., Puerto Rico, and the U.S. Virgin Islands, 2019-2022.
    J Acquir Immune Defic Syndr. 2025 Jul 14. doi: 10.1097/QAI.0000000000003723.
    >> Share

    June 2025
  82. VIOLETTE LR, Delacruz J, Niemann LA, Cannon C, et al
    Preferences for HIV PrEP Products and Delivery Models Among Cisgender Men, Transgender Persons, and Non-binary Individuals Who Have Sex with Men in Seattle, Washington: A Discrete Choice Experiment.
    J Acquir Immune Defic Syndr. 2025 Jun 24. doi: 10.1097/QAI.0000000000003718.
    >> Share

  83. YAO TJ, Zhang J, Malee K, Smith R, et al
    Prenatal Antiretroviral Exposure and Concomitant Neurodevelopmental Problems among 5-year-old Children who are HIV-Exposed and Uninfected.
    J Acquir Immune Defic Syndr. 2025 Jun 24. doi: 10.1097/QAI.0000000000003720.
    >> Share

  84. RANZENIGO M, Diotallevi S, Lolatto R, Castagna A, et al
    Prevalence and incidence of metabolic syndrome in people with HIV receiving cabotegravir and rilpivirine.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003719.
    >> Share

  85. HILFIKER A, Schoepf IC, Avery EF, Ledergerber B, et al
    Mycobacterium tuberculosis Infection and Acute or Subclinical Coronary Artery Disease: the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003714.
    >> Share

  86. GIBBS A, Chirwa E, Harling G, Chimbindi N, et al
    Young men's experiences of violence and poverty and the relationship to sexually transmissible HIV: a cross sectional study from rural South Africa.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003709.
    >> Share

  87. YANG X, Zhang J, Ma Y, Chen S, et al
    Clinical documentation of social determinants of health and its relationship with COVID-19 outcomes among people with and without HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003717.
    >> Share

  88. MA J, Nance RM, Ruderman SA, Drumright LN, et al
    Impact of Depressive Symptom Severity on Stroke Risk in a US Cohort of People with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003710.
    >> Share

  89. XU L, Youngson E, Lin M, Dwivedi R, et al
    Hospital-based healthcare service utilization in persons with HIV with or without mental health and substance use comorbidities.
    J Acquir Immune Defic Syndr. 2025 Jun 19. doi: 10.1097/QAI.0000000000003716.
    >> Share

  90. ANDERSON PL, Coppinger C, Cottrell ML, Marzinke MA, et al
    Recommendations for interpreting intraerythrocytic tenofovir-diphosphate and emtricitabine-triphosphate for PrEP adherence assessment.
    J Acquir Immune Defic Syndr. 2025 Jun 19. doi: 10.1097/QAI.0000000000003715.
    >> Share

  91. KAY ES, Bassler JR, Goebel MC, Browne L, et al
    Retention in HIV Care Still Matters: A Longitudinal Multisite Analysis.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003711.
    >> Share

  92. EDWARDS KA, Long D, Jones KF, Durr AL, et al
    The Skills TO Manage Pain (STOMP) Randomized Trial: Results of antiretroviral therapy adherence, HIV primary care retention, and virologic suppression outcomes.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003706.
    >> Share

  93. ABELMAN RA, Fitzpatrick J, Zawedde J, Beck-Engeser G, et al
    Sex and HIV Modify Immune Activation Biomarkers in Ugandans Post-Tuberculosis.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003713.
    >> Share

  94. AUDET CM, Seabi T, Mabuza W, Mnisi P, et al
    Can traditional health practitioners deliver HIV counseling and testing services? A pilot study in rural South Africa.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003712.
    >> Share

  95. KAMPHUIS AEM, Waalewijn H, Wasmann RE, Bamford A, et al
    Pharmacokinetic data of atazanavir/ritonavir in second-line treatment of children living with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 16. doi: 10.1097/QAI.0000000000003704.
    >> Share

  96. BOLLINGER J, Geller G, Mehta SR, Little SJ, et al
    Clinician perspectives on disclosing public health uses of HIV antiretroviral resistance testing results.
    J Acquir Immune Defic Syndr. 2025 Jun 12. doi: 10.1097/QAI.0000000000003707.
    >> Share

  97. LOGIE CH, Sokolovic N, Casale A, Kennedy VL, et al
    Pathways from childhood abuse history to adulthood mental health among Women Living with HIV in Canada: longitudinal cohort findings.
    J Acquir Immune Defic Syndr. 2025 Jun 10. doi: 10.1097/QAI.0000000000003701.
    >> Share

  98. LABARILE M, Thorball CW, Hodel F, Fellay J, et al
    Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jun 6. doi: 10.1097/QAI.0000000000003702.
    >> Share

  99. NDONGO FA, Kana R, Sambo DA, Ketchaji A, et al
    Effectiveness of community-based peer facilitated psychological and social support interventions on improving mental health in Cameroonian adolescents with perinatal HIV: the IAS-CIPHER-2021/1214-ATE SMAVI controlled randomized trial (November 2021-Ma
    J Acquir Immune Defic Syndr. 2025 Jun 6. doi: 10.1097/QAI.0000000000003705.
    >> Share

  100. SHIVAKOTI R, Giganti MJ, Lederman MM, Ketchum R, et al
    Inflammation, antiretroviral therapy continuation, and HIV disease progression in postpartum women with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 6. doi: 10.1097/QAI.0000000000003703.
    >> Share

  101. EMU B, Kumar PN, Mills A, Berhe M, et al
    Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
    J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699.
    >> Share

  102. COOMES DM, Meisner J, Roberts DA, Rodriguez P, et al
    Maternal HIV retesting during pregnancy and postpartum among high-risk populations in Kenya, South Africa, and Ukraine: Cost-effectiveness of preventing vertical transmission.
    J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003700.
    >> Share

  103. CRESSEY TR, Salvadori N, Rabie H, du Toit S, et al
    Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.
    J Acquir Immune Defic Syndr. 2025;99:195-201.
    >> Share

    May 2025
  104. ZHANG Y, Chow EP, Phillips TR, Fairley CK, et al
    Preferences of men who have sex with men towards the distribution of HIV self-test kits through social networks: A discrete choice experiment.
    J Acquir Immune Defic Syndr. 2025 May 30. doi: 10.1097/QAI.0000000000003696.
    >> Share

  105. ONWUBIKO UN, Benkeser D, Holland DP, Baral SD, et al
    Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.
    J Acquir Immune Defic Syndr. 2025 May 15. doi: 10.1097/QAI.0000000000003698.
    >> Share

  106. HUANG YA, Patel RR, Mann LM, Zhu W, et al
    Out-of-pocket costs for PrEP ancillary services among U.S. commercially insured persons, 2017-2022.
    J Acquir Immune Defic Syndr. 2025 May 14. doi: 10.1097/QAI.0000000000003695.
    >> Share

  107. PATTEN G, Haas AD, Davies MA, Maartens G, et al
    Association between changes in script renewal periods and HIV viral non-suppression: a cohort study of a South African private-sector HIV program.
    J Acquir Immune Defic Syndr. 2025 May 14. doi: 10.1097/QAI.0000000000003697.
    >> Share

  108. SUDDERUDDIN H, Dang Z, Watson B, Atkinson K, et al
    Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples.
    J Acquir Immune Defic Syndr. 2025 May 13. doi: 10.1097/QAI.0000000000003694.
    >> Share

  109. RYAN AS, Briggs BC, Lozano AJ, Iranmanesh A, et al
    Randomized Clinical Trial of High Intensity Exercise in People with HIV: Effects on Muscle Composition and Inflammation.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003692.
    >> Share

  110. DESISTO CL, Dada D, Pathela P, Winer RL, et al
    Vaccine effectiveness against anal HPV infection among men with HIV who have sex with men attending sexual health clinics in three United States cities, 2018-2023.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003691.
    >> Share

  111. GUIGAYOMA J, Biello K, Becker SJ, Ocean E, et al
    High HIV Testing Among Black/Latino Men Who Have Sex with Men Assigned to HIV Self-Testing in a National Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003693.
    >> Share

  112. O'SHEA J, Yuan X, Lu JF, Buchacz K, et al
    Barriers to Rapid Enrollment and ART Initiation Among U.S. HIV Care Facilities.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003690.
    >> Share

  113. ATUJUNA M, Nyamaizi AM, Duby Z, Minnis A, et al
    Men's Voices on Long-Acting Pre-Exposure Prophylaxis Delivery Modalities: Acceptability and Preferences Among Cisgender Men and Men Who Have Sex With Men in South Africa.
    J Acquir Immune Defic Syndr. 2025;99:55-63.
    >> Share

  114. WANG H, Delnoij M, Zimmermann HML, Jonas KJ, et al
    The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.
    J Acquir Immune Defic Syndr. 2025;99:1-8.
    >> Share

    April 2025
  115. LOVELACE TC, Gelhaus SL, Methe B, Mullett SJ, et al
    Identifying Metabolomic Biomarkers of Lung Function Decline in People with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 29. doi: 10.1097/QAI.0000000000003689.
    >> Share

  116. PHAM M, Wickremasingha P, Vargo R, Patel M, et al
    Exploratory Substudy of a Phase 2 Trial to Evaluate the Pharmacokinetic Effect of Once-Monthly Islatravir on Long-Acting Reversible Contraceptives.
    J Acquir Immune Defic Syndr. 2025 Apr 22. doi: 10.1097/QAI.0000000000003678.
    >> Share

  117. WILSON S, Milicic A, Javandel S, Yballa C, et al
    Amyloid-beta PET Positivity Among Cognitively Impaired People with HIV Over Age 60.
    J Acquir Immune Defic Syndr. 2025 Apr 21. doi: 10.1097/QAI.0000000000003686.
    >> Share

  118. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions: Erratum.
    J Acquir Immune Defic Syndr. 2025 Apr 18. doi: 10.1097/QAI.0000000000003684.
    >> Share

  119. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 EHE Jurisdictions: Erratum.
    J Acquir Immune Defic Syndr. 2025 Apr 18. doi: 10.1097/QAI.0000000000003683.
    >> Share

  120. NDONGO FA, Tejiokem MC, Penda CI, Ndiang ST, et al
    IMMUNOLOGICAL AND VIROLOGIC OUTCOMES WITHIN TEN YEARS OF COMBINED ANTIRETROVIRAL THERAPY INITIATED BEFORE ONE YEAR OF AGE IN CAMEROONIAN CHILDREN WITH PERINATAL HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003687.
    >> Share

  121. NAMPOTA-NKOMBA N, Buchwald A, Nyirenda OM, Mkandawire FA, et al
    Association between Maternal HIV and Adverse Birth Outcomes in the Era of Universal Antiretroviral Therapy in Malawi.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003685.
    >> Share

  122. CRANE HM, Ruderman SA, Nance RM, Drumright LN, et al
    Approaches to optimally target frailty screening among people with HIV in clinical care: findings from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS).
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003688.
    >> Share

  123. JONES J, Siegler AJ, Glick JL, Lucas IL, et al
    Brief Report: Potential Gains in PrEP Coverage and Effect on Racial Disparities After Introduction of On-Demand and Long-Acting Injectable PrEP: Preferences of Men Who Have Sex With Men in the United States, 2021-2022.
    J Acquir Immune Defic Syndr. 2025;98:429-433.
    >> Share

  124. SIRIBELLI A, Diotallevi S, Galli L, Muccini C, et al
    Non-liver Malignancies as Main Cause of Mortality After HCV Eradication Among People Living With HIV: Erratum.
    J Acquir Immune Defic Syndr. 2025;98:e16.
    >> Share

  125. DONOSO VA, Chandra S, Zamantakis A, Kassanits J, et al
    Two Pilots of an Implementation Science Training Program for HIV Prevention and Care Service Providers: Lessons Learned and Future Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  126. KHOSROPOUR CM, Means AR, Kerani RP, Murphy EM, et al
    Developing Implementation Science Capacity Within Health Departments Located in Ending the HIV Epidemic Priority Areas.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  127. GARNER BR, Bouris A, Charlebois ED, Li DH, et al
    The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  128. KATOMSKI AS, Pachicano AM, Zamantakis A, Benbow ND, et al
    Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite Qualitative Study.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  129. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 Ending the HIV Epidemic Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  130. MCCOY K, Mantell JE, Deiss R, Liu A, et al
    Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  131. MANTELL JE, Bauman LJ, Bonett S, Buchbinder S, et al
    Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United States: Expanding Access in Nontraditional Settings.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  132. BROWN LL, Batchelder AW, Gondre-Lewis MC, Willie TC, et al
    Innovations to Address Unmet Behavioral Health Needs in National Ending the HIV Epidemic Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  133. JONES JL, Schwartz S, Kassanits JE, Pyra M, et al
    Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded Clinics: Results From a Multisite Survey.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  134. BELTRAN RM, Katomski AS, Bonett S, Cianelli R, et al
    Lessons Learned From Engaging Healthcare Providers in Research on Implementation of HIV Preexposure Prophylaxis.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  135. GIGUERE R, Mmeje O, Patel VV, Felsen UR, et al
    Defining Study Populations in HIV Prevention Implementation Science Studies: A Case Comparison of 3 Ending the HIV Epidemic Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  136. OGUNBAJO A, Martinez O, Akiyama M, Dombrowski JC, et al
    Implementation Science Approaches to Addressing the Social and Structural Determinants of Health of Criminal-Legal Involved People Living With HIV to Improve HIV Care Outcomes.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  137. NOWOTNY KM, Culbertson K, Akiyama MJ, Callen E, et al
    Integrating People With Lived Experience of Carceral System Involvement Into Research: Lessons Learned From Ending the HIV Epidemic Research Teams.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  138. RODRIGUEZ-DIAZ CE, Jaramillo J, Santiago-Rivera Y, Harkness A, et al
    Language Justice in Implementation Science: Experiences Working With Latinxs to End the HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  139. SHAH HS, Serrano PA, Rodriguez-Diaz CE, Page KR, et al
    Not a Monolith: Regional HIV Implementation Science Lessons With Latino/a/x Populations.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  140. MACAPAGAL K, Stoner MCD, Guss CE, Sukhija-Cohen AC, et al
    Lessons Learned in Engaging Adolescents and Young Adults to End the US HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  141. RODRIGUEZ-DIAZ CE, Kopeka MP, Tun W, Santiago-Rodriguez EI, et al
    Communities Started the End of the HIV Epidemic: Experiences With and Recommendations for Conducting Community-Engaged HIV Implementation Research.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  142. LANZI RG, Varley A, Ott C, Wolfner C, et al
    Implementation Science Methods, Challenges, and Associated Solutions: Transportable Lessons Learned and Best Practices From the Second National Meeting for Research and Community Collaboration Toward Ending the HIV Epidemic in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  143. SCHWARTZ S, Benbow N, Brewer RA, Beres LK, et al
    Generating Evidence for Effective HIV Implementation at Scale: The Value and Feasibility of a Network for Implementation Science in HIV.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  144. SIMON CL, Carlisle NA, Kermani M, Cole C, et al
    Community Engagement to Empowerment: Emphasizing Relationships, Process, Resources, and Context to Strengthen Community Engagement in EHE Research Partnerships.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  145. BERES LK, Harkness A, Corcoran J, Datar R, et al
    Improving Community-Engaged Implementation Science: Perspectives From "Ending the HIV Epidemic" Supplement Award Cases in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  146. DATAR R, Schwartz S, Gomez W, Katz DA, et al
    Community-Engaged Research in HIV Implementation Science: Characterizing Academic and Community Partnerships in the "Ending the HIV Epidemic" Supplement Awards.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  147. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  148. GORDON C, Koenig LJ, Psihopaidas D, Refsland E, et al
    Leveraging Implementation Science to End the HIV Epidemic in the United States: Progress and Opportunities for Federal Agencies.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  149. LI DH, Gaines Lanzi R, Pyra M
    Progress and Priorities to End the HIV Epidemic by 2030: Combined Lessons From 120 US Implementation Research Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    >> Share

  150. SETIA WIRAWAN GB, Navin KS, Lila Wulandari LP, Boettiger D, et al
    Retention and viral suppression with differentiated time or space for adolescent and young adult HIV care: a systematic review and meta-analysis.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003681.
    >> Share

  151. MILICIC A, Wilson S, Javandel S, Allen IE, et al
    Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003679.
    >> Share

  152. ZHU W, Huang YA, Kourtis AP, Neblett-Fanfair R, et al
    Trends in HIV preexposure prophylaxis use before and after launch of the Ending the HIV Epidemic in the U.S. initiative, 2016-2023.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003674.
    >> Share

  153. CHEN Y, Montano MA, Naik P, Thuo N, et al
    Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680.
    >> Share

  154. WALL KM, Sullivan P, Shrestha RK, Dana R, et al
    Cost and cost-effectiveness of online recruitment to increase HIV self-testing among Black and Hispanic/Latino men who have sex with men in the United States, 2020-2021.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003666.
    >> Share

  155. MOROZOVA O, Conroy K, Riabokon S, Germanovich M, et al
    HIV Viral Rebound on Dolutegravir, Lopinavir and Efavirenz: National Program Data Analysis from Ukraine.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003676.
    >> Share

  156. BUNTING SR, Feinstein BA, Wilson A, Rivera J, et al
    Preferences for PrEP Implementation and Engagement in the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003675.
    >> Share

  157. IZQUIERDO R, Vallejo A, Suarez-Garcia I, Martin-Hondarza A, et al
    Markers of inflammation and immune dysfunction and non-AIDS cancer risk in adults with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003667.
    >> Share

  158. JAROLIMOVA J, Yan J, Govere S, Shezi S, et al
    Sexually transmitted infection testing integrated with HIV prevention and contraceptive services in hair salons in urban South Africa.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003677.
    >> Share

  159. DUNK CE, Powis KM, Legbedze J, Sun S, et al
    Low placental growth factor levels mid-gestation predict small for gestational age in pregnant women with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003672.
    >> Share

  160. FISHER SA, Jao J, Yee LM, Serghides L, et al
    Fatty acid signatures in people with HIV: association with adverse pregnancy outcomes and offspring anthropometrics.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003665.
    >> Share

  161. ELBUR AI, Mirzazadeh A, Tate M, Suprasert B, et al
    HIV Incidence among People Who Inject Drugs, San Francisco, 2022.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003673.
    >> Share

  162. EDWARDS KA, Smith KJ, Jones KF, Bair MJ, et al
    Cost-Effectiveness of a Tailored Pain Self-Management Intervention Compared to Enhanced Usual Care Among People with HIV and Chronic Pain: An Economic Evaluation.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003671.
    >> Share

  163. SHARMA A, Hoover DR, Shi Q, Daubert E, et al
    Poor Sleep Quality is Associated with Frailty Among Women with and without HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003668.
    >> Share

  164. GOYAL R, Honerkamp-Smith G, Wells A, Little SJ, et al
    Predictive models to identify individuals with HIV at risk of unsuppressed viral load using routine public health data.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003670.
    >> Share

  165. REMERA E, Chammartin F, Nsanzimana S, Malamba SS, et al
    Factors associated with recent HIV infections among newly HIV diagnosed in Rwanda.
    J Acquir Immune Defic Syndr. 2025 Apr 2. doi: 10.1097/QAI.0000000000003669.
    >> Share

  166. WANG RJ, Kunisaki KM, Morris A, Drummond MB, et al
    Brief Report: The Implications of Removing Race From Interpretation of Pulmonary Function Among Persons With or Without HIV.
    J Acquir Immune Defic Syndr. 2025;98:395-400.
    >> Share

  167. TARAMASSO L, Rossotti R, Tavelli A, Santoro MM, et al
    Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort.
    J Acquir Immune Defic Syndr. 2025;98:352-356.
    >> Share

  168. THEODORE DA, Neradilek M, Gillespie K, Edupuganti S, et al
    Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
    J Acquir Immune Defic Syndr. 2025;98:340-345.
    >> Share

  169. ZHU X, Patel EU, Berry SA, Grabowski MK, et al
    Brief Report: Trends in Hospital Readmissions Among Adults With and Without HIV in the United States, 2010-2020.
    J Acquir Immune Defic Syndr. 2025;98:334-339.
    >> Share

    March 2025
  170. BUTTS SA, Johnson AL, Doblecki-Lewis S
    PrEP Beyond the Clinic: Evaluation of a Home-Based PrEP Follow-Up System Among a Cohort of Predominantly Black and Latino Men who Have Sex with Men in South Florida.
    J Acquir Immune Defic Syndr. 2025 Mar 28. doi: 10.1097/QAI.0000000000003664.
    >> Share

  171. BANGA J, Nelson BS, Ajibola G, Mohammed T, et al
    Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003663.
    >> Share

  172. KIPTINNESS C, Mugo N, Mugwanya KK, Ngure K, et al
    THE EFFECT OF PARTNER DELIVERY OF HIV SELF-TEST KITS ON HIV TESTING AND LINKAGE TO CARE IN PUBLIC CLINICS IN KENYA.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003662.
    >> Share

  173. GUTIERREZ JI JR, Montgomery ET, Dilworth SE, McNulty MC, et al
    Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpvirine in three U.S. HIV clinics: A discrete choice experiment.
    J Acquir Immune Defic Syndr. 2025 Mar 13. doi: 10.1097/QAI.0000000000003661.
    >> Share

  174. NJUGUNA I, Moraa H, Mbwayo A, Nyapara F, et al
    "You are the tutor, you are the counselor, you are the school nurse, you are everything": Secondary school staff experience with youth living with HIV.
    J Acquir Immune Defic Syndr. 2025 Mar 11. doi: 10.1097/QAI.0000000000003659.
    >> Share

  175. CHAILLON A, Gaitan NC, Taylor LE, Wu K, et al
    Predictors of Acute HCV Incidence in People with HIV: Insights from a Long-term Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 6. doi: 10.1097/QAI.0000000000003660.
    >> Share

  176. PHILPOTT DC, Curran KG, Russell OO, McClung RP, et al
    HIV Clusters Reported by State and Local Health Departments in the United States, 2020-2022.
    J Acquir Immune Defic Syndr. 2025 Mar 6. doi: 10.1097/QAI.0000000000003658.
    >> Share

  177. DASGUPTA S, Tie Y, Buchacz K, Koenig LJ, et al
    A novel method for assessing poor quality of life among people with HIV.
    J Acquir Immune Defic Syndr. 2025 Mar 5. doi: 10.1097/QAI.0000000000003644.
    >> Share

  178. ZHAO Y, Holtman M, Mudaly V, van Zyl G, et al
    Resistance to Dolutegravir in Treatment-experienced Patients in South Africa: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 3. doi: 10.1097/QAI.0000000000003657.
    >> Share

  179. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2025;98:265-273.
    >> Share

  180. SMITH MK, Luo D, Meng S, Fei Y, et al
    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.
    J Acquir Immune Defic Syndr. 2025;98:224-233.
    >> Share

  181. VERA M, Sila J, Richardson BA, Otieno F, et al
    Brief Report: Effect of Improved Provider Communication and Adherence to Guidelines on PrEP Initiation in Kisumu Kenya.
    J Acquir Immune Defic Syndr. 2025;98:252-256.
    >> Share

    February 2025
  182. MBENGERANWA T, Ziemba L, Brummel SS, Johnston B, et al
    Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial.
    J Acquir Immune Defic Syndr. 2025 Feb 26. doi: 10.1097/QAI.0000000000003656.
    >> Share

  183. SCONZA R, Fernandes G, Bailey H, Peters H, et al
    Outcomes following prenatal exposure to raltegravir-containing antiretroviral therapy: a multi-cohort European study.
    J Acquir Immune Defic Syndr. 2025 Feb 25. doi: 10.1097/QAI.0000000000003645.
    >> Share

  184. PUTHANAKIT T, Aurpibul L, Lopez M, Wang M, et al
    Efficacy and Safety of the Two-Drug Regimen Dolutegravir/Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-label, Phase 3b Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003655.
    >> Share

  185. VINOGRADOV V, Lee YG, Zhakupova G, Mergenova G, et al
    Social Impacts of Multi-City HIV Research Participation Among Sexual and Gender Expansive Individuals in Kazakhstan.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003654.
    >> Share

  186. GRAVETT RM, Long DM, Biello KB, Mayer KH, et al
    Preferences for monthly oral PrEP over other PrEP modalities among a national sample of gay, bisexual, and other men who have sex with men in the United States.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003651.
    >> Share

  187. YOUNG J, Wang S, Sacks-Davis R, Stewart A, et al
    Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003646.
    >> Share

  188. LANG R, Coburn SB, Gill MJ, Grossman J, et al
    The Association of Anemia on Non-AIDS Defining Cancer and Subsequent Survival among People with HIV following Antiretroviral Initiation.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003647.
    >> Share

  189. GATHE JC, Dejesus E, Ramgopal MN, Rolle CP, et al
    Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003648.
    >> Share

  190. SHILABYE PS, Scheuermaier K, Vos-Seda AG, Barth RE, et al
    THE ASSOCIATION BETWEEN HIV-RELATED STIGMA, ART ADHERENCE AND CARDIOVASCULAR DISEASE RISK IN PEOPLE LIVING WITH HIV.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003653.
    >> Share

  191. RAMAKRISHNAN A, Goldstein M, Shetty S, Badell M, et al
    Improving Perinatal HIV Care during the COVID-19 Pandemic: Implementing a Mobile Integrated Health Program to Close the Gap.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003643.
    >> Share

  192. MOCANU V, Brooks HM, Namasopo S, Opoka RO, et al
    The lived experiences of Ugandan community health workers engaged in prevention of vertical transmission of HIV and a capacity-building intervention.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003649.
    >> Share

  193. KOTA KK, Mansergh G, Carnes N, Gelaude D, et al
    Behavioral Readiness for Daily Oral PrEP in a Diverse Sample of Gay, Bisexual, and Other Men who have Sex with Men Who Have Not Been Offered PrEP by a Provider.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003650.
    >> Share

  194. ZHENG A, Fox MP, Greener R, Kileel EM, et al
    Initiation of Dolutegravir vs Efavirenz on Viral Suppression and Retention at 6-months: A Regression Discontinuity Design.
    J Acquir Immune Defic Syndr. 2025 Feb 6. doi: 10.1097/QAI.0000000000003642.
    >> Share

  195. SPINELLI MA, Christopoulos KA
    Reply.
    J Acquir Immune Defic Syndr. 2025;98:e12.
    >> Share

  196. DOMINGUEZ-DOMINGUEZ L, Hamzah L, Fox J, Vincent RP, et al
    Brief Report: Cystatin C Provides Substantially Higher Glomerular Filtration Rate Estimates Than Creatinine in a Subset of Black People With HIV on Current Antiretroviral Regimens.
    J Acquir Immune Defic Syndr. 2025;98:171-175.
    >> Share

  197. TASSIOPOULOS K, John B, Khadraoui A, Salomon L, et al
    Brief Report: Transition Preparation and Post-Transition Evaluation Practices at Adult Clinics That Care for Young Adults With Perinatally Acquired HIV in Massachusetts, United States.
    J Acquir Immune Defic Syndr. 2025;98:103-107.
    >> Share

  198. MAYA S, Sheira LA, Frongillo EA, Pala AN, et al
    Brief Report: Internalized Poverty-Related Stigma and Interpersonal Violence Among Women Living With HIV in the United States.
    J Acquir Immune Defic Syndr. 2025;98:99-102.
    >> Share

    January 2025
  199. MURPHY E, Hoffman S, Ssempijja V, Nalugoda F, et al
    HIV Pre-Exposure Prophylaxis (PrEP) awareness and use among Rakai Community Cohort Study youth aged 15-24.
    J Acquir Immune Defic Syndr. 2025 Jan 31. doi: 10.1097/QAI.0000000000003640.
    >> Share

  200. MARWA MM, Larsen A, Abuna F, Dettinger J, et al
    HIV risk perception and PrEP uptake among pregnant women offered PrEP during antenatal care in Kenya.
    J Acquir Immune Defic Syndr. 2025 Jan 31. doi: 10.1097/QAI.0000000000003641.
    >> Share

  201. MIMIAGA MJ, Kuhns LM, Biello KB, Tian J, et al
    Positive STEPS: Enhancing Medication Adherence and Achieving Viral Load Suppression in Youth Living with HIV in the United States - Results from a Stepped-Care Randomized Controlled Efficacy Trial.
    J Acquir Immune Defic Syndr. 2025 Jan 30. doi: 10.1097/QAI.0000000000003639.
    >> Share

  202. DINIZ CP, Abdul-Massih S, Bagia C, Giguere R, et al
    Rectal Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: An End User Tenofovir Powder Sachet Preparation Feasibility Study (DREAM-04).
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003608.
    >> Share

  203. BAZAZI AR, Thomas M, Vittinghoff E, Walkup J, et al
    Schizophrenia and retention in HIV care among adults insured through Medicaid in the United States: a population-based retrospective cohort study.
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003606.
    >> Share

  204. BAXTER A, Gopalappa C, Islam MH, Viguerie A, et al
    Updates to HIV transmission rate estimates along the HIV care continuum in the United States, 2019.
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003623.
    >> Share

  205. FISK-HOFFMAN RJ, Liu Y, Somboonwit C, Widmeyer M, et al
    What Matters Most for Long-Acting Antiretroviral Therapy? A Best-Worst Scaling Discrete Choice Experiment.
    J Acquir Immune Defic Syndr. 2025 Jan 21. doi: 10.1097/QAI.0000000000003609.
    >> Share

  206. YU B, Jike C, Lan X, Wang J, et al
    Effect of fertility desire-based service on HIV seroconversion among serodiscordant partners: A 12-year retrospective cohort study.
    J Acquir Immune Defic Syndr. 2025 Jan 21. doi: 10.1097/QAI.0000000000003607.
    >> Share

  207. CALZA L, Colangeli V, Giglia M, Rigamonti C, et al
    EFFICACY AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE IN ANTIRETROVIRAL THERAPY-NAIVE PEOPLE LIVING WITH HIV-1 AND WITH HIGH-LEVEL VIREMIA.
    J Acquir Immune Defic Syndr. 2025 Jan 14. doi: 10.1097/QAI.0000000000003600.
    >> Share

  208. SONG W, Mulatu MS, Crepaz N, Wang G, et al
    Association Between County-Level Social Vulnerability and CDC-funded HIV Testing Program Outcomes in the United States, 2020-2022.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003603.
    >> Share

  209. CARBONE A, Vaccher E, Gloghini A, Pria AD, et al
    Management of KSHV/HHV8 positive Multicentric Castleman Disease concurrent with other KSHV/HHV8 positive disorders. An emergent challenge in PLWH.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003604.
    >> Share

  210. MARCUS R, Dasgupta S, Taussig J, Tie Y, et al
    Social Determinants of Health and Unmet Needs for Services among Young Adults with HIV: Medical Monitoring Project, 2018-2021.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003605.
    >> Share

  211. CHAN PA, Goedel WC, Li Y, Mena L, et al
    Impact of Social Determinants of Health on Pre-exposure Prophylaxis Care for HIV Prevention.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003601.
    >> Share

  212. JONES J, Siegler AJ, Glick JL, Lucas I, et al
    Potential gains in PrEP coverage and effect on racial disparities following introduction of on-demand and long-acting injectable PrEP: Preferences of men who have sex with men in the United States, 2021-2022.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003602.
    >> Share

  213. TESORIERO JM, Boos EM, Adamashvili N, Massaroni R, et al
    Assessing Gaps in Integrated HIV and STI Testing Among New York State-Funded Providers by Pre-Exposure Prophylaxis Status: Implications for Status-Neutral Programming.
    J Acquir Immune Defic Syndr. 2025 Jan 6. doi: 10.1097/QAI.0000000000003598.
    >> Share

  214. HAAS AD, Kusejko K, Cavassini M, Gunthard H, et al
    Late re-engagement into HIV care among adults in the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003597.
    >> Share

  215. MOYLE G, Meng F, Wan H, Sklar P, et al
    Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003599.
    >> Share

  216. HORTON RH, Mcintosh A, Ostinelli EG, Harriss E, et al
    Neuropsychiatric Outcomes in Children and Adolescents with Perinatally Acquired HIV: A Systematic Review and Meta Analysis.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003595.
    >> Share

  217. SERUNJOGI R, Mumpe-Mwanja D, Williamson DM, Valencia D, et al
    Risk of adverse birth outcomes and birth defects among women living with HIV on antiretroviral therapy and HIV-negative women in Uganda, 2015-2021.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003596.
    >> Share

  218. L T, F M, D V, S B, et al
    Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003594.
    >> Share

  219. DANG T, Anderson J, Powell AM
    Factors Associated with Retention in HIV Care within 12 months Postpartum: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003593.
    >> Share

  220. ANDERSON KM, Sheth AN, Sales JM
    Exploring PrEP Motivation as a Modifiable Target for HIV Prevention Uptake for Cisgender Women in Atlanta, Georgia.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003587.
    >> Share

  221. ANDERSON K, Rabie H, Eley BS, Frigati L, et al
    High incidence of tuberculosis in young children living with HIV in the Western Cape, South Africa.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003591.
    >> Share

  222. JALIL CM, Teixeira SLM, Coutinho C, Nazer SC, et al
    Impact of COVID-19 Pandemic on HIV Testing, Recent Infections, and Annualized Incidence Among Cisgender Men Who Have Sex With Men and Transgender Women in Brazil.
    J Acquir Immune Defic Syndr. 2025;98:12-19.
    >> Share

  223. MURPHY M, Rogers B, Galipeau D, Toma E, et al
    HIV Pre-exposure Prophylaxis Use Among Men Experiencing Incarceration in the United States: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025;98:41-48.
    >> Share

  224. ABRAHAM BK, Vogler M, Talati A, Suresh P, et al
    Pregnancy Outcomes and All-Cause Mortality After Pregnancy Among US-Born Women With Perinatally Acquired HIV.
    J Acquir Immune Defic Syndr. 2025;98:20-28.
    >> Share

  225. HUANG YA, Lowy E, Zhu W, Yu L, et al
    Brief Report: Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2014 horizontal line 2022.
    J Acquir Immune Defic Syndr. 2025;98:8-11.
    >> Share

    December 2024
  226. GLASS DJ, Kinge M, Njuguna I, McGrath CJ, et al
    Poorer longitudinal growth among HIV exposed compared to unexposed infants in Kenya.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003592.
    >> Share

  227. FISHER MC, Hanna DB, Fazzari M, Felsen UR, et al
    Preadmission VACS Index as a Predictor of Hospital Acute Kidney Injury in People with HIV.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003589.
    >> Share

  228. ROSENBERG NE, Graybill LA, Mtande T, McGrath N, et al
    The impact of a couple-based intervention on one-year viral suppression among pregnant women living with HIV and their male partners in Malawi: A randomized controlled trial.
    J Acquir Immune Defic Syndr. 2024 Dec 23. doi: 10.1097/QAI.0000000000003583.
    >> Share

  229. BEESHAM I, Jaggernath M, Kriel Y, Hao J, et al
    Longitudinal changes in tenofovir and tenofovir-diphosphate concentrations among pregnant women using oral PrEP for HIV prevention: Findings from Durban, South Africa.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003586.
    >> Share

  230. GUTREUTER S, Denhard L, Logan JE, Blanton J, et al
    Model-Based Prioritization of Adolescent Girls and Young Women for HIV Prevention Services Based on Data from 13 Sub-Saharan African Countries.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003588.
    >> Share

  231. HUANG YA, Chang MH, Zhu W, Hoover KW, et al
    Uptake of HIV Preexposure Prophylaxis Among Medicare Beneficiaries - United States, 2014-2021.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003590.
    >> Share

  232. CHAWKI S, Hamet G, Brun A, Lourenco N, et al
    Pancreatic cancer in people with HIV: a case-control study.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003585.
    >> Share

  233. TAN DHS, Antinori A, Eu B, Galindo Puerto MJ, et al
    Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Acquir Immune Defic Syndr. 2024 Dec 16. doi: 10.1097/QAI.0000000000003584.
    >> Share


  234. Early Efficacy and Safety of the Third Dose Inactivated COVID-19 Vaccine Among People Living With HIV: Erratum.
    J Acquir Immune Defic Syndr. 2024;97:e30.
    >> Share

  235. THORP M, Phiri S, Phiri K, Robson I, et al
    Brief Report: Stated Preferences for Long-Acting Injectable ART Among Mobile Men Living With HIV in Malawi: A Qualitative Study.
    J Acquir Immune Defic Syndr. 2024;97:e25-e29.
    >> Share

  236. HASTIE E, Srivatsa MS, Gianella S, Cottrell M, et al
    Brief Report: Genital Microbiome, Inflammation, and Tenofovir Levels in Transgender Men and Cisgender Women Taking Oral PrEP.
    J Acquir Immune Defic Syndr. 2024;97:477-481.
    >> Share

  237. PAINE EA, Appenroth M, Scheim A, Goldrich M, et al
    Brief Report:Availability of and Interest in Gender-Affirming Care, PrEP, and HIV Prevention Services in a Global Sample of Transmasculine Persons.
    J Acquir Immune Defic Syndr. 2024;97:471-476.
    >> Share

  238. KRENISKE P, Nalugoda F, Chen I, Parate N, et al
    Brief Report: Antiretroviral Treatment Use Over Time Among Adolescents and Young Adults in the Rakai Community Cohort Study, 2011-2020.
    J Acquir Immune Defic Syndr. 2024;97:433-438.
    >> Share

  239. GOLUB SA, Wolfer C, Chastain CA
    INCREASING THE ACCESSIBILITY AND RELEVANCE OF IMPLEMENTATION SCIENCE FOR FRONT-LINE IMPLEMENTERS.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003580.
    >> Share

  240. VOLPI C, Adebiyi R, Chama J, Ononaku U, et al
    Impact of Age of Sexual Debut on HIV Care Engagement among Sexual and Gender Minorities in Nigeria.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003574.
    >> Share

  241. WU L, Ssebuliba T, Muwonge TR, Bambia F, et al
    ALIGNMENT OF PREP USE WITH POTENTIAL HIV EXPOSURE IN YOUNG WOMEN AND MEN IN UGANDA.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003573.
    >> Share

  242. KUGLEN B, Clay C, Boothroyd D, Bennett CL, et al
    Estimated Impact of HIV Testing on Length of Stay at Visits to United States Emergency Departments, 2018-2021.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003575.
    >> Share

  243. GOLUB SA, Wolfer C, Beacham A, Lane BV, et al
    DEVELOPING A PRACTICE-DRIVEN TAXONOMY OF IMPLEMENTATION STRATEGIES FOR HIV PREVENTION.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003581.
    >> Share

  244. MATTIE H, Goyal R, De Gruttola V, Onnela JP, et al
    A review of network models for HIV spread.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003578.
    >> Share

  245. WANG RJ, Kunisaki KM, Morris A, Drummond MB, et al
    The implications of removing race from interpretation of pulmonary function among persons with or without HIV.
    J Acquir Immune Defic Syndr. 2024 Dec 3. doi: 10.1097/QAI.0000000000003579.
    >> Share

  246. MUNROE S, Schackman BR, Madkins K, Saber R, et al
    Economic Evaluation of delivering an evidence-based online HIV prevention program to MSM via direct-to-consumer marketing versus community-based organization recruitment.
    J Acquir Immune Defic Syndr. 2024 Dec 2. doi: 10.1097/QAI.0000000000003572.
    >> Share

  247. HO K, Hoesley C, Anderson PL, Fernandez-Romero JA, et al
    Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).
    J Acquir Immune Defic Syndr. 2024;97:379-386.
    >> Share

  248. CARNEIRO PB, Radix AE, Golub S, Grosskopf N, et al
    PrEP Use in a US National Sample of Trans Men and Other Transmasculine People Who Have Sex With Men: A Longitudinal Analysis.
    J Acquir Immune Defic Syndr. 2024;97:357-363.
    >> Share

  249. MORGAN E, Punches B, Failla M
    Self-Reported Diagnosis of Autism Is Associated With a Lower Likelihood of HIV Testing.
    J Acquir Immune Defic Syndr. 2024;97:e6-e9.
    >> Share

  250. MATONE M, Piscaglia M, Giacomelli A, Moschese D, et al
    Brief Report: Switching to Long-Acting CAB/RPV: Data From an Italian Monocentric Cohort.
    J Acquir Immune Defic Syndr. 2024;97:e1-e5.
    >> Share

  251. MAYER C, Agbobli-Nuwoaty SE, Li J, Carlson K, et al
    Brief Report: Unmet Need for Solid Organ Transplantation Among People With HIV and End-Stage Kidney or Liver Disease: A Brief Report From the HIV Outpatient Study, 2009-2023.
    J Acquir Immune Defic Syndr. 2024;97:397-401.
    >> Share

  252. WANG Z, Patterson W, Rajulu DT
    Brief Report: Aging With HIV: An Epidemiological Profile of Persons With Diagnosed HIV Aged 50 Years and Older in New York State, 2012-2021.
    J Acquir Immune Defic Syndr. 2024;97:353-356.
    >> Share

    November 2024
  253. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 27. doi: 10.1097/QAI.0000000000003563.
    >> Share

  254. DUNN DT, McCabe L, Ward D, Phillips AN, et al
    Assessing whether providing regular, free HIV self-testing kits reduces the time to HIV diagnosis: an internet-based, randomised controlled trial in men who have sex with men.
    J Acquir Immune Defic Syndr. 2024 Nov 22. doi: 10.1097/QAI.0000000000003564.
    >> Share

  255. EGER WH, Shaw LC, Biello KB, Lopez C, et al
    HIV pre-exposure prophylaxis prescription initiation and maintenance among homeless-experienced people who use drugs.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003568.
    >> Share

  256. SMITH MK, Luo D, Meng S, Fei Y, et al
    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003565.
    >> Share

  257. DEVANATHAN AS, Poliseno AJ, White NR, Schauer AP, et al
    A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003570.
    >> Share

  258. POWIS KM, Pinilla M, McMorrow F, Stek A, et al
    Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003571.
    >> Share

  259. MANAVALAN P, Gadkowski LB, Sachdeva A, Guha S, et al
    Acceptability of multi-level sexual health interventions and sexually transmitted infection screening and testing among persons with HIV across three clinical sites in Florida.
    J Acquir Immune Defic Syndr. 2024 Nov 20. doi: 10.1097/QAI.0000000000003569.
    >> Share

  260. YANG X, Cai R, Ma Y, Zhang HH, et al
    Using machine learning techniques to predict viral suppression among people with HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 19. doi: 10.1097/QAI.0000000000003561.
    >> Share

  261. DOS SANTOS FC, Garofalo R, Kuhns L, Scherr T, et al
    Evaluating the Effectiveness of a Mobile Health Intervention on Enhancing HIV Knowledge in Sexual and Gender Minority Men.
    J Acquir Immune Defic Syndr. 2024 Nov 19. doi: 10.1097/QAI.0000000000003562.
    >> Share

  262. PEREZ-BRUMER A, Apedaile D, Leon-Morris F, Huerta L, et al
    Migration is associated with increased HIV vulnerability among young transgender women in Lima, Peru.
    J Acquir Immune Defic Syndr. 2024 Nov 15. doi: 10.1097/QAI.0000000000003560.
    >> Share

  263. ALESSIA S, Sara D, Laura G, Camilla M, et al
    Non-liver malignancies as main cause of mortality after HCV eradication among people living with HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 7. doi: 10.1097/QAI.0000000000003559.
    >> Share

  264. HILL L, Yin J, Patel N, Abulhosn K, et al
    Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine.
    J Acquir Immune Defic Syndr. 2024 Nov 5. doi: 10.1097/QAI.0000000000003556.
    >> Share

  265. HUMPHREY J, Kipchumba B, Alera M, Sang E, et al
    Outcomes After Loss to Follow-Up for Pregnant and Postpartum Women Living With HIV and Their Children in Kenya: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2024;97:242-252.
    >> Share

  266. BAILEY JR, Fonseca E, Borsa A, Hawryluk E, et al
    Three Novel Patient-Reported Outcome Measures to Assess the Patient Experience With Daily and Weekly HIV Oral Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;97:286-295.
    >> Share

  267. AULD SC, Harrington KRV, Nguyen MLT, Colasanti JA, et al
    Brief Report: Alternative Pulmonary Function Measures of Emphysema in People With HIV.
    J Acquir Immune Defic Syndr. 2024;97:282-285.
    >> Share

  268. COMINS CA, Mcingana M, Genberg B, Mulumba N, et al
    Contextual Factors Influencing Implementation of HIV Treatment Support Strategies for Female Sex Workers Living With HIV in South Africa: A Qualitative Analysis Using the Consolidated Framework for Implementation Research.
    J Acquir Immune Defic Syndr. 2024;97:273-281.
    >> Share

  269. LEE CL, Low A, Kreniske P, Mugurungi O, et al
    HIV Outcomes Among Women Living With HIV Who Experienced Early Sexual Violence Across Four Sub-Saharan African Countries.
    J Acquir Immune Defic Syndr. 2024;97:253-260.
    >> Share

  270. CHANDRAN A, Feng X, Coburn SB, Kasaie P, et al
    The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD.
    J Acquir Immune Defic Syndr. 2024;97:232-241.
    >> Share

  271. ZHABOKRITSKY A, Klein M, Harris M, Loutfy M, et al
    Prevalence and Correlates of Frailty Among Older Adults Living With HIV in the CHANGE HIV Cohort.
    J Acquir Immune Defic Syndr. 2024;97:226-231.
    >> Share

  272. CHAGOMERANA MB, Moser CB, Kang M, Umbleja T, et al
    Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067.
    J Acquir Immune Defic Syndr. 2024;97:216-225.
    >> Share

  273. WULANDARI LPL, Negara SNS, Mashuri YA, Wahyuningtias SD, et al
    A Systematic Review and Meta-analysis of the Impact of the COVID-19 Pandemic on Access to HIV Pre-exposure Prophylaxis: Lessons for Future Public Health Crises.
    J Acquir Immune Defic Syndr. 2024;97:208-215.
    >> Share

  274. HAZIM CE, Coutinho J, Crocker J, Asbjornsdottir K, et al
    Posttrial Experiences in Sustainment of a Scaled Model of the Systems Analysis and Improvement Approach (SAIA-SCALE) in the Absence of External Funding in Manica Province, Mozambique.
    J Acquir Immune Defic Syndr. 2024;97:203-207.
    >> Share

    October 2024
  275. YOUNG R, Ssekasanvu J, Kagaayi J, Ssekubugu R, et al
    HIV and viremia prevalence in non-migrating members of migrant households in southern Uganda: A cross-sectional population-based study.
    J Acquir Immune Defic Syndr. 2024 Oct 31. doi: 10.1097/QAI.0000000000003553.
    >> Share

  276. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States".
    J Acquir Immune Defic Syndr. 2024 Oct 30. doi: 10.1097/QAI.0000000000003554.
    >> Share

  277. TIAMIYU AB, Hu F, Kokogho A, Charurat ME, et al
    Discussion of HIV and Other Sexually Transmitted Infections with Sex Partners of Nigerian Men who have Sex with Men and Transgender Women: Implications for Interventions to Promote Safer Sex Practices.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003552.
    >> Share

  278. BERNARD C, Font H, Zotova N, Wools-Kaloustian K, et al
    Accuracy of alternative PHQ-9 scoring algorithms to screen for depression in people living with HIV in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003551.
    >> Share

  279. KRIS H, Anders B, Daniela K VS, Kees B, et al
    Hepatitis C treatment and behavioural risk among men who have sex with men with HIV: comparing interferon and direct-acting antiviral eras.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003550.
    >> Share

  280. TAIWO BO, Kuhns LM, Agbaji O, David A, et al
    A Stepped-Wedge, Cluster-Randomized, Multisite Study of Text Messaging Plus Peer Navigation to Improve Adherence and Viral Suppression Among Youth on Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024 Oct 18. doi: 10.1097/QAI.0000000000003549.
    >> Share

  281. MAGAGNOLI J, Cummings TH, Wyatt MD, Shtutman M, et al
    Schizophrenia, Off-Label Antipsychotics, and Dementia Risk in People with HIV.
    J Acquir Immune Defic Syndr. 2024 Oct 17. doi: 10.1097/QAI.0000000000003545.
    >> Share

  282. ROGERS B, Ramsey S, Ames E, Gomes N, et al
    Addressing barriers to implementing and scaling PrEP in carceral settings: Applying insights from implementation science.
    J Acquir Immune Defic Syndr. 2024 Oct 10. doi: 10.1097/QAI.0000000000003547.
    >> Share

  283. RACCAGNI AR, Passini F, Diotallevi S, Lolatto R, et al
    Gaps in HIV Pre-exposure Prophylaxis Acceptance: Findings from an Outpatient HIV Testing Service in Italy.
    J Acquir Immune Defic Syndr. 2024 Oct 8. doi: 10.1097/QAI.0000000000003544.
    >> Share

  284. FINN B, Vanessa M, Xochitl LM, Emily P, et al
    Addressing methamphetamine use is essential to stopping HIV transmission.
    J Acquir Immune Defic Syndr. 2024 Oct 7. doi: 10.1097/QAI.0000000000003542.
    >> Share

  285. KOTA KK, Eppink S, Gant Z, Chesson H, et al
    Racial and Ethnic Disparities in HIV Diagnosis Rates by Social Determinants of Health at the Census Tract Level among Adults in the United States and Puerto Rico, 2021.
    J Acquir Immune Defic Syndr. 2024 Oct 4. doi: 10.1097/QAI.0000000000003541.
    >> Share

  286. BURNETT J, Olansky E, Baugher AR, Lee K, et al
    Intersecting structural and psychosocial conditions: investigating injection drug use and HIV among transgender women.
    J Acquir Immune Defic Syndr. 2024 Oct 4. doi: 10.1097/QAI.0000000000003543.
    >> Share

  287. COLER B, Smith GH, Arora AK, Wells A, et al
    Quality of Life in People with HIV at the End of Life: Preliminary Results from the Last Gift Observational Cohort Study.
    J Acquir Immune Defic Syndr. 2024 Oct 3. doi: 10.1097/QAI.0000000000003536.
    >> Share


  288. Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;97:202.
    >> Share

  289. ORR JE, Velazquez J, Schmickl CN, Bosompra NO, et al
    Sleep, Sleep Apnea, and Fatigue in People Living With HIV.
    J Acquir Immune Defic Syndr. 2024;97:192-201.
    >> Share

  290. LAZZARO A, Vai D, Barco A, Stroffolini G, et al
    Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:180-191.
    >> Share

  291. MASHETO G, Brummel SS, Ziemba L, Shepherd J, et al
    Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
    J Acquir Immune Defic Syndr. 2024;97:172-179.
    >> Share

  292. DEBROY P, Barrett BW, Erlandson KM, Budoff M, et al
    Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus.
    J Acquir Immune Defic Syndr. 2024;97:165-171.
    >> Share

  293. AOUIZERAT BE, Garcia JN, Domingues CV, Xu K, et al
    Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size.
    J Acquir Immune Defic Syndr. 2024;97:156-164.
    >> Share

  294. BELTRAN RM, Hunter LA, Packel LJ, De Martini L, et al
    A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California.
    J Acquir Immune Defic Syndr. 2024;97:142-149.
    >> Share

  295. MACGOWAN RJ, Chavez PR, Dana R, Hannah M, et al
    Efficacy of Internet Recruitment and HIV Self-Testing for Diagnosing HIV Infections Among Black and Hispanic/Latino MSM and Transgender Women in 11 US States, 2020-2021.
    J Acquir Immune Defic Syndr. 2024;97:133-141.
    >> Share

  296. MUJUGIRA A, Karungi B, Nakyanzi A, Bagaya M, et al
    Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;97:125-132.
    >> Share

  297. MCDONALD SA, Yeung A, Nandwani R, Clutterbuck D, et al
    A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individuals Newly Diagnosed With HIV Infection in Scotland.
    J Acquir Immune Defic Syndr. 2024;97:117-124.
    >> Share

  298. YANG X, Zhang J, Chen S, Liu Z, et al
    COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
    J Acquir Immune Defic Syndr. 2024;97:107-116.
    >> Share

  299. YIGIT I, Budhwani H, Rainer CB, Claude K, et al
    Associations Between PrEP Stigma, PrEP Confidence, and PrEP Adherence: Conditional Indirect Effects of Anticipated HIV Stigma.
    J Acquir Immune Defic Syndr. 2024;97:99-106.
    >> Share

  300. OKEGBE T, Bishop KM, Rose J, Srivastava M, et al
    Trends in the Uptake of Index Testing among Adolescents in USAID-Supported PEPFAR Programs, October 2017- September 2022.
    J Acquir Immune Defic Syndr. 2024 Oct 1. doi: 10.1097/QAI.0000000000003540.
    >> Share

  301. FAIRLIE L, Brummel S, Ziemba L, Coletti A, et al
    Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.
    J Acquir Immune Defic Syndr. 2024;97:150-155.
    >> Share

    September 2024
  302. HONG HANH NT, Phuong Tram PT, Thanh Ha HT, Duc BH, et al
    Detection of antiretroviral drug-resistant mutations and HIV-1 subtypes in circulation among men who have sex with men, SEM females and female sex workers: results of Vietnam's HIV Sentinel Surveillance Plus (HSS+) system, 2018 - 2020.
    J Acquir Immune Defic Syndr. 2024 Sep 26. doi: 10.1097/QAI.0000000000003537.
    >> Share

  303. EDELMAN EJ, Dziura J, Deng Y, DePhilippis D, et al
    Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial.
    J Acquir Immune Defic Syndr. 2024 Sep 25. doi: 10.1097/QAI.0000000000003534.
    >> Share

  304. GUTEMA Y, Lulseged S, Getachew M, Getahun M, et al
    Index-linked Assisted HIV Self-Testing for Children 2-14 Years: Results of a Pilot Evaluation in Ethiopia.
    J Acquir Immune Defic Syndr. 2024 Sep 25. doi: 10.1097/QAI.0000000000003533.
    >> Share

  305. ZINGONI ZM, Okano JT, Ponce J, Dullie L, et al
    Modeling travel-time to HIV treatment in Malawi: identifying rural-urban and wealth inequities.
    J Acquir Immune Defic Syndr. 2024 Sep 24. doi: 10.1097/QAI.0000000000003539.
    >> Share

  306. JALIL CM, Maia Teixeira SL, Coutinho C, Nazer SC, et al
    Impact of Covid-19 pandemic on HIV testing, recent infections and annualized incidence among cisgender men who have sex with men and transgender women in Brazil.
    J Acquir Immune Defic Syndr. 2024 Sep 18. doi: 10.1097/QAI.0000000000003531.
    >> Share

  307. SELZER L, VanderVeen LA, Parvangada A, Martin R, et al
    Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People with HIV-1 Suppressed by Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024 Sep 18. doi: 10.1097/QAI.0000000000003528.
    >> Share

  308. ANGULIQUE O, Thomas T, Karen M, Monique J, et al
    Motivational Enhancement System for Adherence (MESA) for Adolescents and Young Adults Newly Recommended to Start Antiretroviral Therapy (ART).
    J Acquir Immune Defic Syndr. 2024 Sep 17. doi: 10.1097/QAI.0000000000003530.
    >> Share

  309. CORBETT C, van Rensburg R, Brey N, O'Hagan S, et al
    Timing of ART initiation associated with HIV-associated stroke.
    J Acquir Immune Defic Syndr. 2024 Sep 17. doi: 10.1097/QAI.0000000000003529.
    >> Share

  310. WEIJSENFELD A, van der Knaap L, Sattoe J, van Staa A, et al
    Health-related quality of life in young adults with perinatal HIV after transfer to adult health care in the Netherlands.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003526.
    >> Share

  311. REISNER SL, Humes E, Stevenson M, Cooney EE, et al
    Site-based and Digital Cohort Participation Among Transgender Women in the Eastern and Southern USA: Findings from the LITE Study.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003527.
    >> Share

  312. MICHAEL HU, Brouillette MJ, Tamblyn R, Fellows LK, et al
    Disentangling the Effects of Comorbidity and Polypharmacy on Cognitive Function and Physical Frailty in Individuals with HIV.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003523.
    >> Share

  313. BELL GJ, Chen JS, Maierhofer CN, Matoga M, et al
    Updated Risk Score Algorithms for Acute HIV Infection Detection at a Sexually Transmitted Infections Clinic in Lilongwe, Malawi.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003519.
    >> Share

  314. DEJESUS E, Towner WJ Jr, Gathe JC, Cash RB, et al
    Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003524.
    >> Share

  315. EL-HIBRI F, Al-Hindawi A, Singh S, Bower M, et al
    Outcomes of lymphoma patients admitted to the ICU are not influenced by HIV status: a retrospective, observational cohort study.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003522.
    >> Share

  316. BATOHI N, Shalekoff S, Martinson NA, Ebrahim O, et al
    HIV-1 Elite Controllers are Characterised by Elevated Levels of CD69-Expressing Natural Killer Cells.
    J Acquir Immune Defic Syndr. 2024 Sep 2. doi: 10.1097/QAI.0000000000003518.
    >> Share

  317. DA CUNHA GH, Fontenele MSM, Galvao MTG, Dantas MB, et al
    Factors Associated With Symptoms of Anxiety and Depression in People Living With HIV in Northeast Brazil.
    J Acquir Immune Defic Syndr. 2024;97:87-98.
    >> Share

  318. BERNARD I, Ransy DG, Brophy J, Kakkar F, et al
    Lower Neutrophil Count Without Clinical Consequence Among Children of African Ancestry Living With HIV in Canada.
    J Acquir Immune Defic Syndr. 2024;97:78-86.
    >> Share

  319. PENCE BW, Darnell D, Ranna-Stewart M, Psaros C, et al
    Provocative Findings From a Transdiagnostic Counseling Intervention to Improve Psychiatric Comorbidity and HIV Care Engagement Among People With HIV: A Pilot Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:68-77.
    >> Share

  320. DEROSE KP, Palar K, Then-Paulino A, Han B, et al
    Changes in HIV Internalized and Experienced Stigmas and Social Support After an Urban Gardens and Peer Nutritional Counseling Intervention Among People With HIV and Food Insecurity in the Dominican Republic.
    J Acquir Immune Defic Syndr. 2024;97:55-62.
    >> Share

  321. FULTON J, Novitsky V, Gillani F, Guang A, et al
    Integrating HIV Cluster Analysis in Everyday Public Health Practice: Lessons Learned From a Public Health--Academic Partnership.
    J Acquir Immune Defic Syndr. 2024;97:48-54.
    >> Share

  322. NETHI AK, Karam AG, Alvarez KS, Luque AE, et al
    Using Machine Learning to Identify Patients at Risk of Acquiring HIV in an Urban Health System.
    J Acquir Immune Defic Syndr. 2024;97:40-47.
    >> Share

  323. ROGERS BG, Toma E, Harkness A, Arnold T, et al
    "Why Not Just go on PrEP?": A Study to Inform Implementation of an HIV Prevention Intervention Among Hispanic/Latino Men Who Have Sex With Men in the Northeastern United States.
    J Acquir Immune Defic Syndr. 2024;97:26-39.
    >> Share

  324. SPINELLI MA, Johnson MO, Lisha NE, Jain JP, et al
    Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States.
    J Acquir Immune Defic Syndr. 2024;97:13-18.
    >> Share

  325. UNTERNAHER J, Koay WLA, Mareuil J, Williams T, et al
    Progress in Eliminating Perinatal HIV Transmission in the Metropolitan DC Area Between 2018-2022.
    J Acquir Immune Defic Syndr. 2024;97:6-12.
    >> Share

  326. YAN CY, Cooley SA, Ances BM
    Veterans Aging Cohort Study Index 2.0 Shows Improved Discrimination of Neurocognitive Impairment and Frailty in People with HIV.
    J Acquir Immune Defic Syndr. 2024;97:63-67.
    >> Share

  327. COONEY EE, Reisner SL, Poteat TC, Althoff KN, et al
    Brief Report: Interest in Long-acting Injectable PrEP Among Transgender Women in Eastern and Southern United States.
    J Acquir Immune Defic Syndr. 2024;97:19-25.
    >> Share

  328. SIMMS V, Kranzer K, Dziva Chikwari C, Dauya E, et al
    Brief Report: Youth Who Acquired HIV Perinatally Have Poorer Viral Suppression Than Those Who Acquired HIV Later in Life: Findings From a Population Survey in Zimbabwe.
    J Acquir Immune Defic Syndr. 2024;97:1-5.
    >> Share

    August 2024
  329. WALTERS MK, Korenromp EL, Yakusik A, Wanyeki I, et al
    Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module.
    J Acquir Immune Defic Syndr. 2024 Aug 27. doi: 10.1097/QAI.0000000000003514.
    >> Share

  330. REITSEMA M, Wallinga J, van Sighem AI, Bezemer D, et al
    Impact of varying pre-exposure prophylaxis programs on HIV and Neisseria gonorrhoeae transmission among MSM in the Netherlands: a modelling study.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003511.
    >> Share

  331. JOHN SA, Walsh JL, Doherty RM, Rine SR, et al
    Determinants of potential HIV vaccine uptake among young sexual minoritized men 17-24 years old.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003517.
    >> Share

  332. MBABAZI P, Chen G, Ritchie CS, Tsai AC, et al
    Prevalence and correlates of frailty among older people with and without HIV in rural Uganda.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003513.
    >> Share

  333. JIAMSAKUL A, Rupasinghe D, Woolley I, Choi JY, et al
    HIV treatment outcomes after 10 years on ART in the TREAT Asia Observational Database (TAHOD) and Australian HIV Observational Database (AHOD).
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003515.
    >> Share

  334. NALINTYA E, Sekar P, Namakula OL, Tadeo KK, et al
    The diagnostic performance of the Visitect Advanced Disease point-of-care CD4 platform: a pragmatic mixed-methods multisite validation, costing, and qualitative analysis.
    J Acquir Immune Defic Syndr. 2024 Aug 19. doi: 10.1097/QAI.0000000000003505.
    >> Share

  335. MSOSA TC, Swai I, Aarnoutse R, Rinke de Wit TF, et al
    The Effect of Real-Time Medication Monitoring-Based Digital Adherence Tools on Adherence to Antiretroviral Therapy and Viral Suppression in People Living With HIV: A Systematic Literature Review and Meta-Analysis.
    J Acquir Immune Defic Syndr. 2024;96:411-420.
    >> Share

  336. SHORER EF, Dastgheyb RM, French AL, Daubert E, et al
    Tryptophan-Kynurenine Pathway Activation and Cognition in Virally Suppressed Women With HIV.
    J Acquir Immune Defic Syndr. 2024;96:494-500.
    >> Share

  337. MARTIN TCS, Smith LR, Anderson C, Little SJ, et al
    Randomized Controlled Trial of 60 minutes for Health With Rapid Antiretroviral Therapy to Reengage Persons With HIV Who Are Out of Care.
    J Acquir Immune Defic Syndr. 2024;96:486-493.
    >> Share

  338. JONSSON-OLDENBUTTEL C, Ghosn J, van der Valk M, Florence E, et al
    Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    J Acquir Immune Defic Syndr. 2024;96:472-480.
    >> Share

  339. HOFFMANN CJ, Herce ME, Chimoyi L, Smith HJ, et al
    Reaching for 90:90:90 in Correctional Facilities in South Africa and Zambia: Virtual Cross-Section of Coverage of HIV Testing and Antiretroviral Therapy During Universal Test and Treat Implementation.
    J Acquir Immune Defic Syndr. 2024;96:465-471.
    >> Share

  340. ROY PALADHI U, Katz DA, Otieno G, Hughes JP, et al
    Effectiveness of Using Additional HIV Self-Test Kits as an Incentive to Increase HIV Testing Within Assisted Partner Services.
    J Acquir Immune Defic Syndr. 2024;96:457-464.
    >> Share

  341. NICOLAU IA, Moineddin R, Brooks JD, Antoniou T, et al
    Associations of CD4 Cell Count Measures With Infection-Related and Infection-Unrelated Cancer Risk Among People With HIV.
    J Acquir Immune Defic Syndr. 2024;96:447-456.
    >> Share

  342. HERNANDEZ AL, Hilton JF, Weatherly CS, Berry-Lawhorn JM, et al
    Prevalence of Anal Human Papillomavirus Infection and Anal High-Grade Squamous Intraepithelial Lesions Among Men Who Have Sex With Men 50 Years and Older Living With or Without HIV.
    J Acquir Immune Defic Syndr. 2024;96:439-446.
    >> Share

  343. BARTH SK, Monroe AK, Houston P, Benator D, et al
    COVID-19 Incidence, Risk Factors, Impact, and Related Stigma Among a Cohort of Persons With HIV in Washington, DC.
    J Acquir Immune Defic Syndr. 2024;96:429-438.
    >> Share

  344. SAVINELLI S, McGettrick P, Garcia Leon AA, Tinago W, et al
    Obesity is associated with higher levels of circulating cytokines involved in the development of cardiovascular disease in people living with HIV.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003508.
    >> Share

  345. RUSSELL ES, Zhou M, Song Y, Barak N, et al
    Patterns of HIV treatment preferences among people with diverse demographic, social, and behavioral characteristics who are living with HIV in the United States.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003509.
    >> Share

  346. ISLAS-MUNOZ B, Chavez-Galan L, Ramon-Luing L, Flores-Gonzalez J, et al
    Comparison of IL-6, IL-10, and TNFalpha levels between PLWHIV with and without Kaposi Sarcoma and healthy controls.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003507.
    >> Share

  347. CYKTOR JC, Yeh E, Ribaudo H, Hoeth D, et al
    Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.
    J Acquir Immune Defic Syndr. 2024;96:481-485.
    >> Share

  348. ROSS JL, Teeraananchai S, Avihingsanon A, Lee MP, et al
    Brief Report: Depression, Substance Use, and Factors Associated With Sexual Risk Behaviors Among Adults Living With HIV in the Asia-Pacific Region.
    J Acquir Immune Defic Syndr. 2024;96:421-428.
    >> Share

  349. MISTRI P, Tomescu S, Bokolo S, De Nooy A, et al
    Evaluation of four interventions using behavioural economics insights to increase demand for voluntary medical male circumcision in South Africa through the MoyaApp: A quasi-experimental study.
    J Acquir Immune Defic Syndr. 2024 Aug 9. doi: 10.1097/QAI.0000000000003504.
    >> Share

  350. LANG R, Coburn SB, Gill MJ, Grossman J, et al
    THE ASSOCIATION OF ANEMIA WITH SURVIVAL AMONG PEOPLE WITH HIV FOLLOWING ANTIRETROVIRAL INITIATION IN THE NA-ACCORD 2007-2016.
    J Acquir Immune Defic Syndr. 2024 Aug 9. doi: 10.1097/QAI.0000000000003502.
    >> Share

  351. LUC CM, Max B, Perez S, Herrera K, et al
    Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic.
    J Acquir Immune Defic Syndr. 2024 Aug 5. doi: 10.1097/QAI.0000000000003500.
    >> Share

  352. LIPPMAN SA, Grignon JS, Ditshwane B, West RL, et al
    Results of the Sukuma Ndoda ("Stand up, Man") HIV Self-Screening and Assisted Linkage to Care Project in Johannesburg: A Quasi-Experimental Pre-Post Evaluation.
    J Acquir Immune Defic Syndr. 2024;96:367-375.
    >> Share

  353. GARRETT N, Dintwe O, Monaco CL, Jones M, et al
    Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
    J Acquir Immune Defic Syndr. 2024;96:350-360.
    >> Share

  354. HALLARN J, Scheim AI, Bauer GR
    Pre-exposure Prophylaxis Awareness and Use Among Transgender and Nonbinary Individuals in Canada.
    J Acquir Immune Defic Syndr. 2024;96:341-349.
    >> Share

  355. ROHR JK, Manne-Goehler J, Gomez-Olive FX, Kahn K, et al
    The HIV Care Cascade for Older Adults in Rural South Africa: A Longitudinal Cohort Study (2014-2019).
    J Acquir Immune Defic Syndr. 2024;96:334-340.
    >> Share

  356. ROSEN AD, Javanbakht M, Shoptaw SJ, Seamans MJ, et al
    Associations of Sleep Deficiency With Sexual Risk Behaviors and HIV Treatment Outcomes Among Men Who Have Sex With Men Living With or at High Risk of Acquiring HIV.
    J Acquir Immune Defic Syndr. 2024;96:326-333.
    >> Share

  357. TSENG AS, Mugwanya KK, Szpiro AA, van Heerden A, et al
    Estimating the Effect of COVID-19 Pandemic Restrictions on Self-reported Antiretroviral Therapy Use and Late Refill Visits Among People Living With HIV in Rural South Africa.
    J Acquir Immune Defic Syndr. 2024;96:318-325.
    >> Share


  358. Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention: Erratum.
    J Acquir Immune Defic Syndr. 2024;96:410.
    >> Share

  359. MORRISON S, Batting J, Wanga V, Beesham I, et al
    True and false positive HIV point of care test results in a prospective multinational study of at-risk African women: implications for large-scale repeat HIV testing in HIV prevention programs.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003497.
    >> Share

  360. FOLEY JD, Bernier LB, Ngo L, Batchelder AW, et al
    Evaluating the Efficacy of Psycho-Behavioral Interventions for Cardiovascular Risk among People Living with HIV: A Systematic Review and Meta-Synthesis of Randomized Controlled Trials.
    J Acquir Immune Defic Syndr. 2024;96:399-409.
    >> Share

  361. BISHOP MD, Korutaro V, Boyce CL, Beck IA, et al
    Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
    J Acquir Immune Defic Syndr. 2024;96:385-392.
    >> Share

  362. NEARY J, Njuguna I, Wagner AD, Richardson BA, et al
    Brief Report: Group-Based Trajectory Modeling to Determine Long-Term HIV Viral Load Trends Among Children With HIV in Kenya.
    J Acquir Immune Defic Syndr. 2024;96:311-317.
    >> Share

  363. TUKEI VJ, Machekano R, Tchounga BK, Khumalo PN, et al
    Follow-up Outcomes of Children, Adolescents and Young People on Darunavir-Based Third-line Antiretroviral Therapy - Observational Cohort from Nine African Countries.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003498.
    >> Share

  364. COBURN SB, Pimentel N, Leyden W, Kitahata M, et al
    Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV.
    J Acquir Immune Defic Syndr. 2024;96:393-398.
    >> Share

  365. D'ANTONI ML, Andreatta K, Chang S, Cox S, et al
    Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;96:380-384.
    >> Share

  366. PHOGOLE CM, Bekker A, Cressey TR, Ferris W, et al
    Brief Report: Can a Fraction of the Dolutegravir Dispersible Tablet Solution be Used to Dose Neonates?
    J Acquir Immune Defic Syndr. 2024;96:376-379.
    >> Share

    July 2024
  367. LEONG TD, Nel J, Jamieson L, Osih R, et al
    A review and economic analysis of the dapivirine vaginal ring as HIV pre-exposure prophylaxis for women, to inform South African public-sector guidelines.
    J Acquir Immune Defic Syndr. 2024 Jul 25. doi: 10.1097/QAI.0000000000003496.
    >> Share

  368. SINGOGO E, Weir SS, Kudowa E, Chagomerana M, et al
    Characterising HIV acquisition risk, treatment gaps and populations reached through venue-based outreach and clinical services in Blantyre, Malawi: findings from a district-wide CLOVE Study.
    J Acquir Immune Defic Syndr. 2024 Jul 18. doi: 10.1097/QAI.0000000000003493.
    >> Share

  369. MCCRIMMON T, Collins LF, Pereyra M, Platamone C, et al
    Likelihood of Trying Long-Acting Injectable Antiretroviral Therapy Among Women With HIV in Nine Sites Across the United States.
    J Acquir Immune Defic Syndr. 2024;96:e23-e27.
    >> Share

  370. OYUGA R, Amadi E, Blanco N, Ndaga A, et al
    Effects of Multimonth Dispensing on Viral Suppression and Continuity in Treatment Among Children Living With HIV Aged 2-9 Years: A Cohort Study in Western Kenya.
    J Acquir Immune Defic Syndr. 2024;96:290-298.
    >> Share

  371. CALABRESE SK, Zaheer MA, Flores JJ, Kalwicz DA, et al
    Messaging About HIV Transmission Risk When Viral Load Is Undetectable: Reactions and Perceived Accuracy Among US Sexual Minority Men.
    J Acquir Immune Defic Syndr. 2024;96:270-279.
    >> Share

  372. AUDET CM, Graves E, Shepherd BE, Prigmore HL, et al
    Partner-Based HIV Treatment for Seroconcordant Couples Attending Antenatal and Postnatal Care in Rural Mozambique: A Cluster Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2024;96:259-269.
    >> Share

  373. VITRUK O, Ihnatiuk AP, Kazanzhy AP, Shvab M, et al
    Uptake and Persistent Use of HIV Preexposure Prophylaxis Among Key Populations: Results From Ukraine's Scaled National Preexposure Prophylaxis Program.
    J Acquir Immune Defic Syndr. 2024;96:241-249.
    >> Share

  374. BAKOYANNIS G, Elul B, Wools-Kaloustian KK, Brown S, et al
    Modeling the HIV Cascade of Care Using Routinely Collected Clinical Data to Guide Programmatic Interventions and Policy Decisions.
    J Acquir Immune Defic Syndr. 2024;96:223-230.
    >> Share

  375. PETERS BA, Hanna DB, Xue X, Weber K, et al
    Menopause and Estrogen Associations With Gut Barrier, Microbial Translocation, and Immune Activation Biomarkers in Women With and Without HIV.
    J Acquir Immune Defic Syndr. 2024;96:214-222.
    >> Share

  376. CHOI J, May SB, Dang BN, Markham C, et al
    Acceptability of a Future HIV Vaccine: A Rapid Scoping Review.
    J Acquir Immune Defic Syndr. 2024;96:197-207.
    >> Share

    June 2024
  377. DIRAJLAL-FARGO S, Sattar A, Strah M, Karungi C, et al
    Immune activation is associated with neurocognitive performance in Ugandan Adolescents living with HIV.
    J Acquir Immune Defic Syndr. 2024 Jun 21. doi: 10.1097/QAI.0000000000003483.
    >> Share


  378. Short-term Outcomes From a Cluster Randomized Evaluation of Adherence Clubs as Part of Differentiated HIV Care in South Africa: Retraction.
    J Acquir Immune Defic Syndr. 2024;96:e14.
    >> Share


  379. Perception and Emotional Experiences of Infant Feeding Among Women Living With HIV in a High-Income Setting: A Longitudinal Mixed Methods Study: Erratum.
    J Acquir Immune Defic Syndr. 2024;96:e12-e13.
    >> Share

  380. IANNONE V, Ciccullo A, Moschese D, Giacomelli A, et al
    Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort.
    J Acquir Immune Defic Syndr. 2024;96:e10-e11.
    >> Share

  381. JI C, Chen L, Kaypaghian M
    Effects of Combination of Ethanol With Ritonavir, Lopinavir or Darunavir on Expression and Localization of the ER-Associated Set Protein and Infection of HIV-1 Pseudovirus in Primary Human Cells.
    J Acquir Immune Defic Syndr. 2024;96:e6-e10.
    >> Share

  382. BENNETT CL, Saxena M, Boothroyd D, Mahmoud-Werthmann S, et al
    Association Between Social Vulnerability and US HIV Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2024;96:e4-e6.
    >> Share

  383. ZHOU S, Cluver L, Knight L, Edun O, et al
    Longitudinal Trajectories of Antiretroviral Treatment Adherence and Associations With Durable Viral Suppression Among Adolescents Living With HIV in South Africa.
    J Acquir Immune Defic Syndr. 2024;96:171-179.
    >> Share

  384. WHITE DAE, Godoy A, Jewett M, Burns M, et al
    Outcomes of an Emergency Department Program to Identify and Link Patients at Increased Risk for Acquiring HIV Infection to Outpatient HIV Prevention Services: The HIV PreventED Program.
    J Acquir Immune Defic Syndr. 2024;96:147-155.
    >> Share

  385. ROSENTHAL M, Patterson W, Rajulu DT
    Missed Opportunities: Characteristics of People Who Received a Concurrent HIV/AIDS Diagnosis in New York State From 2016 to 2021.
    J Acquir Immune Defic Syndr. 2024;96:130-135.
    >> Share

  386. BECKER M, Mishra S, Bhattacharjee P, Musyoki H, et al
    Differential Burden of HIV Among Adolescent Girls and Young Women by Places Associated With Sex Work: An Observational Study in Mombasa, Kenya.
    J Acquir Immune Defic Syndr. 2024;96:121-129.
    >> Share


  387. Short-Term Outcomes From a Cluster Randomized Evaluation of Adherence Clubs as Part of Differentiated HIV Care in South Africa [RETRACTED].
    J Acquir Immune Defic Syndr. 2024;96:e15-e22.
    >> Share

  388. WANDIKA B, Nyapara F, Aballa C, Richardson BA, et al
    Lower self-reported ART adherence among adolescents in boarding schools compared to day schools.
    J Acquir Immune Defic Syndr. 2024;96:101-105.
    >> Share

    May 2024

  389. Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study): Erratum.
    J Acquir Immune Defic Syndr. 2024;96:e3.
    >> Share

  390. RAMBIKI E, Rambiki K, Khalani J, Huwa J, et al
    Letters to the Editor Low Rates of Side Effects in Paclitaxel Chemotherapy for Kaposi Sarcoma and Feasibility of Treatment in Outpatient ART Clinic Settings in Malawi.
    J Acquir Immune Defic Syndr. 2024;96:e1-e2.
    >> Share

  391. WELD ED, Ogasawara K, Fuchs EJ, Louissaint N, et al
    Mapping Colorectal Distribution of Cell-free and Cell-associated HIV Surrogates Following Simulated Anal Intercourse to Aid Rectal Microbicide Development.
    J Acquir Immune Defic Syndr. 2024;96:18-22.
    >> Share

  392. REIS K, Wolf A, Perumal R, Seepamore B, et al
    Differentiated service delivery framework for people with multidrug-resistant tuberculosis and HIV co-infection.
    J Acquir Immune Defic Syndr. 2024;96:34-39.
    >> Share

    April 2024
  393. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:e8-e11.
    >> Share

  394. KABAMI J, Koss CA, Sunday H, Biira E, et al
    Randomized Trial of Dynamic Choice HIV Prevention at Antenatal and Postnatal Care Clinics in Rural Uganda and Kenya.
    J Acquir Immune Defic Syndr. 2024;95:447-455.
    >> Share

  395. YOUNGUI BT, Atwine D, Otai D, Vasiliu A, et al
    Integration of HIV Testing in a Community Intervention for Tuberculosis Screening Among Household Contacts of Patients with Tuberculosis in Cameroon and Uganda.
    J Acquir Immune Defic Syndr. 2024;95:431-438.
    >> Share

  396. SHADE SB, Gutin SA, Agnew E, Grignon JS, et al
    Cost Analysis of Short Messaging Service and Peer Navigator Interventions for Linking and Retaining Adults Recently Diagnosed With HIV in Care in South Africa.
    J Acquir Immune Defic Syndr. 2024;95:417-423.
    >> Share

  397. FU W, McClymont E, Av-Gay G, Dorling M, et al
    Retrospective Cohort Study on the Impact of the COVID-19 Pandemic on Pregnancy Outcomes for Women Living With HIV in British Columbia.
    J Acquir Immune Defic Syndr. 2024;95:411-416.
    >> Share

  398. MOAWAD MHED, Mohamed Shalaby MM, Hamouda E, Mahfouz A, et al
    Risk of Stroke Among HIV Patients: A Systematic Review and Meta-analysis of Global Studies and Associated Comorbidities.
    J Acquir Immune Defic Syndr. 2024;95:399-410.
    >> Share

  399. ERENRICH RK, Braun RA, Torres-Mendoza DM, Stevenson OL, et al
    Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention.
    J Acquir Immune Defic Syndr. 2024;95:463-469.
    >> Share

  400. MUTETWA T, Liu Y, Silvera R, Evans M, et al
    Host Nuclear Genome Copy Number Variations Identify High-Risk Anal Precancers in People Living with HIV.
    J Acquir Immune Defic Syndr. 2024 Apr 15. doi: 10.1097/QAI.0000000000003409.
    >> Share

  401. ERLY S, Menza TW, Granillo L, Navejas M, et al
    Impact of COVID-19 on People Living with HIV: Data from Five Medical Monitoring Project Sites, 2020-2022.
    J Acquir Immune Defic Syndr. 2024 Apr 2. doi: 10.1097/QAI.0000000000003403.
    >> Share

  402. KENNEDY CE, Yeh PT, Verster A, Luhmann N, et al
    Do Peer Navigators Improve Initiation and Retention in HIV/VH/STI Treatment Programs for People From Key Populations? A Systematic Review of Effectiveness, Values and Preferences, and Cost.
    J Acquir Immune Defic Syndr. 2024;95:305-312.
    >> Share

  403. VOLK JE, Leyden WA, Lea AN, Lee C, et al
    Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;95:362-369.
    >> Share

  404. FRANCE AM, Panneer N, Farnham PG, Oster AM, et al
    Simulation of Full HIV Cluster Networks in a Nationally Representative Model Indicates Intervention Opportunities.
    J Acquir Immune Defic Syndr. 2024;95:355-361.
    >> Share

  405. LOGAN NZ, Kilmarx PH, Rolle I, Patel HK, et al
    Brief Report: Self-Reported HIV-Positive Status but Subsequent HIV-Negative Test Results in Population-Based HIV Impact Assessment Survey Participants-11 Sub-Saharan African Countries, 2015-2018.
    J Acquir Immune Defic Syndr. 2024;95:313-317.
    >> Share

    March 2024
  406. HICKEY MD, Grochowski J, Mayorga-Munoz F, Oskarsson J, et al
    Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed.
    J Acquir Immune Defic Syndr. 2024 Mar 27. doi: 10.1097/QAI.0000000000003421.
    >> Share

  407. LINNEMAYR S, Wagner Z, Saya UY, Stecher C, et al
    Behavioral economic incentives to support HIV care: Results from a randomized controlled trial in Uganda.
    J Acquir Immune Defic Syndr. 2024 Mar 27. doi: 10.1097/QAI.0000000000003420.
    >> Share

  408. QIAN Y, Zhang P, Wang L, Suo J, et al
    The association of intraocular efavirenz concentrations and HIV-1 viral load among persons with HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003426.
    >> Share

  409. BUNTING SR, Feinstein BA, Vidyasagar N, Sheth NK, et al
    Psychiatry and Family Medicine Residents' Likelihood of Prescribing HIV Pre-Exposure Prophylaxis (PrEP) to Patients with Mental Illness and HIV Vulnerability.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003423.
    >> Share

  410. PATEL D, Williams WO, Wright C, Essuon A, et al
    CDC-Funded HIV Testing and Undiagnosed HIV Infection in Ending the HIV Epidemic in the U.S. Jurisdictions.
    J Acquir Immune Defic Syndr. 2024 Mar 23. doi: 10.1097/QAI.0000000000003424.
    >> Share

  411. WEISER J, Tie Y, Crim SM, Riedel DJ, et al
    Do HIV Care Outcomes Differ by Provider Type?
    J Acquir Immune Defic Syndr. 2024 Mar 7. doi: 10.1097/QAI.0000000000003410.
    >> Share

  412. MADLALA HP, Myer L, Geffen H, Rusch J, et al
    Inflammatory markers in pregnancy are associated with postpartum weight in South African women living with HIV on antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2024 Mar 4. doi: 10.1097/QAI.0000000000003406.
    >> Share

  413. NUNEZ I, Ceballos-Liceaga SE, Torre A, Garcia-Rodriguez G, et al
    Clinical features and outcomes of mpox in people with and without HIV: a national comparative study.
    J Acquir Immune Defic Syndr. 2024 Mar 4. doi: 10.1097/QAI.0000000000003407.
    >> Share

  414. HANLEY S, Moodley D, Naidoo M, Brummel SS, et al
    THE IMPACT OF REGULAR SCREENING AND LIFESTYLE MODIFICATION ON CARDIOVASCULAR DISEASE RISK FACTORS IN SOUTH AFRICAN WOMEN LIVING WITH HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003387.
    >> Share

  415. OBOHO IK, Esber AL, Dear N, Paulin HN, et al
    Advanced HIV Disease in East Africa and Nigeria, in The African Cohort Study (AFRICOS).
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003392.
    >> Share

  416. BEN FARHAT J, TiendrebeogoMD T, Malateste K, Poda A, et al
    Effects of the Covid-19 pandemic on ART initiation and access to HIV viral load monitoring in adults living with HIV in West Africa: a regression discontinuity analysis.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003404.
    >> Share

  417. TANAKA T, Oshima K, Kawano K, Tashiro M, et al
    Nationwide Longitudinal Annual Survey of HIV/AIDS Referral Hospitals in Japan From 1999-2021: Trend in Non-AIDS-Defining Cancers Among HIV-1-Infected Individuals.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003389.
    >> Share

  418. CALZA L, Giglia M, Viale P
    Relationship Between Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease in Patients With HIV-1 Infection.
    J Acquir Immune Defic Syndr. 2024;95:e5-e7.
    >> Share

  419. MCCRARY AW, Hung F, Foster MC, Koech M, et al
    Letter to the Editor: Cardiac Dysfunction Among Youth With Perinatal HIV Acquisition and Exposure.
    J Acquir Immune Defic Syndr. 2024;95:e2-e4.
    >> Share

  420. NABUKALU D, Yiannoutsos CT, Semeere A, Musick BS, et al
    Mortality Among HIV-Infected Adults on Antiretroviral Therapy in Southern Uganda.
    J Acquir Immune Defic Syndr. 2024;95:268-274.
    >> Share

  421. VAN HEERDEN JK, Meintjes G, Barr D, Zhao Y, et al
    Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:260-267.
    >> Share

  422. NGUMBAU NM, Neary J, Wagner AD, Abuna F, et al
    Cofactors of Partner HIV Self-testing and Oral PrEP Acceptance Among Pregnant Women at High Risk of HIV in Kenya.
    J Acquir Immune Defic Syndr. 2024;95:238-245.
    >> Share

    February 2024
  423. OPSTEEN S, Fram T, Files JK, Levitan EB, et al
    Impact of Chronic HIV Infection on Acute Immune Responses to SARS-CoV-2.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003399.
    >> Share

  424. DE WIT S, Bonnet F, Osiyemi O, Bisshop F, et al
    Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003395.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016